Methods and compositions related to therapeutic peptides for cancer therapy

By developing the anti-cancer peptide ELANE to cleave the proteolytic fragment of CD95 and combining with the synergistic effect of ECP, selective killing of multiple cancer cells is achieved, and the problem of toxicity of existing anti-cancer compositions is solved, which improves the therapeutic effect and enhances the Immune response.

CN119015448APending Publication Date: 2024-11-26UNIVERSITY OF CHICAGO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411342304.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2018-12-20
Filing Date
2019-12-20
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing anti-cancer compositions are difficult to balance a wide range of anti-cancer efficacy with toxicity to normal cells when treating cancer, and the heterogeneity and metastasis of cancer cells make the treatment more difficult.

Method used

An anti-cancer peptide ELANE was developed to selectively kill cancer cells by cutting CD95 proteolytic fragments, leveraging the synergistic effect of ELANE and ECP to enhance the killing effect, and attenuate tumor growth through IT delivery of ELANE.

Benefits of technology

ELANE has shown extensive anti-cancer efficacy and low toxicity, is effective against a variety of cancer cells, and IT delivery methods have weakened tumor growth, increased the number of immune cells in the tumor, and improved the therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005060050520000042
    Figure BDA0005060050520000042
  • Figure BDA0005060050520000043
    Figure BDA0005060050520000043
  • Figure BDA0005060050520000046
    Figure BDA0005060050520000046
Patent Text Reader

Abstract

Embodiments of the present invention provide a solution to problems associated with balancing patient toxicity and the broad efficacy of cancer therapy. In particular, embodiments relate to anti-cancer peptides that exhibit broad anti-cancer efficacy while having limited toxicity to normal cells or non-cancer cells.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of a Chinese invention patent application filed on December 20, 2019, with application number 201980092976.7 and invention name “Methods and compositions related to therapeutic peptides for cancer therapy”.

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims priority to U.S. Provisional Patent Application No. 62 / 782,690, filed on December 20, 2018, the entire contents of which are incorporated herein by reference. Technical Field

[0004] Embodiments of the compositions and methods described herein relate generally to the fields of molecular biology, medicine, and cancer therapy. In particular, embodiments relate to cancer therapy and anti-cancer peptide compositions. Background Art

[0005] Cancer is a proliferative disease of mutations that exhibits a high degree of spatial and temporal genetic heterogeneity (Stratton et al., Nature, 2009; Vogelstein et al., Science, 2013). In addition to overcoming this heterogeneity, eradicating tumor cells while preserving non-cancerous cells remains a daunting task. For these reasons, it has been challenging to identify agents that have broad efficacy against cancer types and maintain specificity to limit host toxicity.

[0006] Broad efficacy and specificity are integral properties of innate immunity. The innate immune system evolved to defend against a wide range of infectious pathogens, including bacteria, fungi, and protozoa, whose genetic diversity far exceeds that of cancer. As a key effector of innate immunity, neutrophils eliminate genetically diverse pathogens and may therefore ideally function quite well in cancer. In fact, human blood polymorphonuclear neutrophils (PMNs) can kill cancer cells (Sagiv, Cell Rep., 2015; Yan et al., Oncoimmunology, 2014), and their therapeutic potential is being explored in clinical trials designed to deliver them as cell therapies. Despite the growing attention paid to human PMNs, the mechanisms by which they kill cancer cells are not fully understood.

[0007] In contrast to the anti-cancer function of PMNs, many studies have shown that tumor-associated neutrophils (TANs) promote tumorigenesis. This contradiction may be due to the origin and activation state of neutrophils, which can produce significant functional differences (Coffelt et al., Nat Rev Cancer, 2016; Eruslanov et al., Trends Cancer, 2017; Kruger et al., PLoS Pathog., 2015). For example, mouse studies have shown that tumor cells hijack neutrophils to release molecules that promote metastatic spread (Coffelt et al., Nature, 2015; Finisguerra et al., Nature, 2015). In addition, increased TAN accumulation is a poor prognostic marker for many cancer types (Coffelt et al., Nat Rev Cancer, 2016; Shen et al., PLoS One, 2014; Powell et al., Immunol., 2016).

[0008] There remains a need for additional anticancer compositions and additional therapies for treating cancer that have broad anticancer efficacy and limited patient toxicity. Summary of the invention

[0009] Embodiments of the present invention provide solutions to problems associated with balancing patient toxicity with broad efficacy of cancer therapy. In particular, embodiments relate to anticancer peptides that exhibit broad anticancer efficacy with limited toxicity to normal or non-cancer cells.

[0010] Given that human PMNs release extracellular factors that kill a variety of pathogens, the inventors sought to explore whether these factors have similar abilities to kill cancer cells. Using this strategy, ELANE was identified as a major anticancer protein released by human PMNs, whose mechanism of action involves the activation of V 220 / A 221 and I 331 / Q 332 ELANE cleaves human CD95 (hCD95) at the site of the mitochondria to release a proteolytic fragment containing the death domain (DD), which selectively kills cancer cells. ELANE has been shown to have broad anticancer efficacy and selectivity in multiple models.

[0011] ELANE has several interesting properties in preclinical models. First, its ability to kill a variety of cancer cells enables implementation without knowledge of their genetics. Second, its specificity for cancer cells relative to non-cancerous cells may limit potential toxicity. Third, preliminary studies have shown that it is challenging for cancer cells to acquire resistance to ELANE. Mechanistically, it has been proposed that these properties stem from ELANE's ability to target CD95. In fact, ELANE's killing program, broad efficacy, specificity, and drug resistance closely mimic those reported in cancer cells treated with shRNA to reduce CD95 levels (L. Chen et al., Nature, 2010), but with an important difference. The proposed mechanism involves CD95 gain of function (i.e., release of DD-containing fragments) rather than loss of function (i.e., CD95 knockdown). CD95 is known to exert both pro-apoptotic and anti-apoptotic effects depending on the physiological context (Martin-Villalba, Liorens-Bobadilla, Wollny. Trends Mol Med, 2013), and the study identified ELANE as a potential therapeutic approach that could exploit its pro-apoptotic function.

[0012] Studies by the present inventors have shown that ELANE proteolytically releases CD95 DD to selectively kill a wide range of cancer cells. Indeed, transient overexpression of full-length CD95 (aa 1-335) or a C-terminal CD95 peptide containing two cleavage sites (aa.212-335) accelerated ELANE-mediated killing in human cancer cells, while transient overexpression of the N-terminal domain (aa1-209) had no effect. However, in the absence of ELANE, transient overexpression of these hCD95 proteins / peptides was not sufficient to kill cancer cells. Induction of apoptosis in the absence of ELANE required expression of a C-terminal hCD95 peptide that mimics ELANE cleavage at one or two sites (site 1: aa 221-335; site 2: aa 212-331; two sites: aa 221-331). Demonstration that these hCD95 peptides can kill multiple types of human cancer cells without harming non-cancerous cells supports the approach of delivering specific CD95 peptides or DNA encoding CD95 peptides for the treatment of many cancers.

[0013] The data show that some human CD95 peptides (which contain ELANE cleavage sites) are not toxic to cancer cells and only make ELANE more effective. On the other hand, in the absence of ELANE, transient expression of human CD95 peptides that mimic ELANE cleavage at one or two sites kills cancer cells. The C peptide is not toxic, but C1 (mimicking cleavage at site 1), C2 (mimicking cleavage at site 2), and C1-2 (mimicking cleavage at both sites) are toxic. In addition, the N-terminal domain peptides of CD95 and full-length CD95 are not toxic to cancer cells. Finally, the results show that the killing mechanism induced by expression of the C1-2 peptide in MDA-MB-231 cells is the same as that of treating these cells with ELANE (i.e., inhibition of survival pathways, and induction of DNA damage, mitochondrial ROS, and apoptotic effectors).

[0014] To investigate whether expression of the CD95 C1-2 peptide could attenuate tumor growth in vivo, the researchers established MDA-MB-231 cancer cells (TNBC) that stably expressed CD95C or C1-2 peptide under the control of a doxycycline-inducible promoter. In in vitro studies, doxycycline treatment induced the expression of both proteins. Consistent with the transient expression system, cells induced to express the C1-2 peptide underwent apoptosis, whereas those induced to express the C peptide did not. In addition, doxycycline-inducible expression of the C1-2 peptide in MCF10a cells (non-cancerous cells) failed to induce apoptosis. Analysis of different C1-2 peptide-expressing colonies of MDA-MB-231 cells showed that the extent of apoptosis was significantly positively correlated with the expression level of C1-2. MDA-MB-231 cells expressing the doxycycline-inducible C1-2 peptide were injected into the mammary fat of mice, allowing tumors to grow to approximately 100 mm 3 At this point, doxycycline was administered to mice either intraperitoneally or via food. The results showed that inducing C1-2 expression in MDA-MB-231 cells reduced tumor growth and increased CD45 in tumors. + The number of immune cells.

[0015] Certain embodiments relate to therapeutic or anticancer compositions comprising various combinations of anticancer peptides or variants thereof, expression vectors or expression cassettes encoding the same. The compositions in certain aspects may include one or more than one peptide comprising, consisting essentially of, or consisting of: the amino acid sequence or Segment and / or and / or Certain embodiments relate to one or more than one peptide or variant thereof having an amino acid sequence that is more than 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 of SEQ ID NO: 2. 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 94, 96, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123 or 124 consecutive amino acids (including all values ​​and ranges therebetween) have 90, 92, 94, 96, 98, 99 to 100% identity, including all values ​​and ranges therebetween.The functional segment of the anticancer peptide can be selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86 , 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118 or 119 and ends with amino acid 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123 or 124. In certain aspects, the anti-cancer peptides described herein can be modified by chemical modification of amino acid side chains (e.g., cross-linking, glycosylation, etc.) or by including a heterologous peptide sequence at the amino or carboxyl terminus of the peptide.

[0016] The anticancer peptides may each be present in the composition at a concentration of 1, 50, 100, 150, 200, 250, 300, 350, 400, 450 μg / mL to 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 μg / mL; or 1, 10, 20, 30, 40, 50, 60, 70, 80, 90 mg / mL to 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200 mg / mL, including all ranges and values ​​therebetween.

[0017] Certain embodiments relate to one or more than one anticancer peptide and / or a composition comprising the same. In some aspects, one or more than one peptide component has 90% to 100% identity with a peptide or its functional segment selected from SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5. In some aspects, the peptide has an amino acid sequence with at least 90% identity with the amino acid sequence of SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4. The peptide component can be coupled to a substrate. In some aspects, the substrate is a delivery vehicle. The delivery vehicle can be a nanoparticle (e.g., a liposome).

[0018] Certain embodiments relate to a method for treating cancer, comprising administering to a subject suffering from cancer an effective amount of a therapeutic composition comprising one or more than one peptide, the peptide having 90% to 100% identity with a peptide selected from SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or a functional segment thereof. The therapeutic composition can be administered by injection. In some aspects, the therapeutic composition is administered intratumorally (e.g., by intratumoral injection). The cancer can be bladder cancer, blood cancer, bone cancer, bone marrow cancer, brain / nervous system cancer, breast cancer, colorectal cancer, esophageal cancer, gastrointestinal cancer, head cancer, kidney cancer, liver cancer, lung cancer, nasopharyngeal cancer, neck cancer, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, gastric cancer, testicular cancer, tongue cancer or uterine cancer. In some aspects, the peptide is present at a dose of 0.001 mg / kg to 10 mg / kg body weight, preferably at least, at most or about 0.1 to 5 mg / kg body weight, and most preferably 0.5 to 1 mg / kg body weight. In other aspects, the method may include administering a second anticancer therapy. The second anti-cancer therapy can be chemotherapy, radiation therapy, immunotherapy (such as a checkpoint inhibitor), or anti-hormone therapy.

[0019] Certain embodiments relate to a method of inducing apoptosis in a cancer cell, comprising contacting the cancer cell with an effective amount of one or more than one peptide, wherein the peptide has 90% to 100% identity with a peptide selected from SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or a functional segment thereof. The cancer cell may be in a bladder tumor, a blood tumor, a bone tumor, a myeloma, a brain / nervous system tumor, a breast tumor, a colorectal tumor, an esophageal tumor, a gastrointestinal tumor, a head tumor, a kidney tumor, a liver tumor, a lung tumor, a nasopharyngeal tumor, a neck tumor, an ovarian tumor, a pancreatic tumor, a prostate tumor, a skin tumor, a stomach tumor, a testicular tumor, a tongue tumor, or a uterine tumor.

[0020] It was found that the anticancer peptides described herein are fragments of human CD95 isoform 1, which have Accession No. NP_000034.1, which is incorporated herein by reference as of the filing date of this application). Amino acids 1 to 25 are signal peptides, and the mature form comprises amino acids 26 to 335. Certain embodiments relate to one or more peptides or variants thereof having an amino acid sequence that is 90, 92, 94, 96, 98, 99 to 100% identical to more than 10, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250 or 255 consecutive amino acids of SEQ ID NO: 1, including all values ​​and ranges therebetween. In certain aspects, the anticancer peptides described herein can be modified by chemical modification of the amino acid side chains (e.g., cross-linking, glycosylation, etc.) or by including a heterologous peptide sequence at the amino or carboxyl terminus of the peptide. The N terminus referred to herein is from amino acids 1 to 209 of (SEQ ID NO: 1), and the C terminus referred to herein is from amino acids 212 to 335 of (SEQ ID NO: 1).

[0021] The compositions described herein can kill a variety of cancer cells, regardless of the genetics of the cancer cells. Therefore, the compositions described herein can treat various types of cancer. In certain aspects, the cancer is bladder cancer, blood cancer, bone cancer (e.g., osteosarcoma), bone marrow cancer (e.g., leukemia), brain / nervous system (e.g., neuroblastoma, glioblastoma), breast cancer, colorectal cancer (e.g., colon cancer), esophageal cancer, gastrointestinal cancer, head cancer, kidney cancer, liver cancer (e.g., hepatocellular carcinoma), lung cancer (e.g., non-small cell lung cancer), nasopharyngeal cancer, neck cancer, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer (e.g., melanoma), stomach cancer, testicular cancer, tongue cancer, or uterine cancer. The compositions described herein are toxic to cancer cells, but are non-toxic or have limited toxicity to non-cancerous cells.

[0022] Certain embodiments relate to methods of killing cancer cells by contacting cancer cells or tumors with an effective amount of a therapeutic anticancer peptide composition. In some aspects, the anticancer peptide composition is administered to a patient suffering from cancer. In some aspects, the cancer is bladder cancer, blood cancer, bone cancer, bone marrow cancer, brain cancer, breast cancer, colorectal cancer, esophageal cancer, gastrointestinal cancer, head cancer, kidney cancer, liver cancer, lung cancer, nasopharyngeal cancer, neck cancer, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, stomach cancer, testicular cancer, tongue cancer or uterine cancer. In some aspects, the anticancer peptide composition may further comprise an additional anticancer agent or be administered in combination with an additional anticancer agent to enhance the effectiveness of the peptide composition. In some aspects, these additional anticancer agents may be administered before; during; after; before and during; before and after; during and after; or before, during and after the administration of the polypeptide composition. In some aspects, the composition described herein may be administered before; during; after; before and during; before and after; during and after; or before, during and after the administration of immunotherapy, chemotherapy, anti-hormone therapy or radiotherapy. In certain aspects, the peptide compositions described herein are administered in combination with chemotherapy, such as doxorubicin and / or paclitaxel.

[0023] Certain embodiments relate to expression vectors or expression cassettes encoding one or more anti-cancer peptides. Such vectors or cassettes may be administered to a subject for the purpose of expressing one or more anti-cancer peptides in or near a target cancer or tumor.

[0024] The term "effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.

[0025] An "effective amount" of an anticancer agent (e.g., a peptide composition described herein) that reduces cancer cell growth refers to an amount that is capable of reducing the growth of certain cancer cells or tumor cells to some extent. The term includes an amount that can cause growth inhibition, cell growth inhibition, and / or cytotoxic effects and / or apoptosis of cancer or tumor cells.

[0026] A "therapeutically effective amount" with respect to the treatment of cancer refers to an amount that is capable of causing one or more of the following effects: (1) inhibiting cancer or tumor growth to some extent, including slowing growth or completely stopping growth; (2) reducing the number of cancer cells or tumor cells; (3) reducing the size of the tumor; (4) inhibiting (i.e., reducing, slowing down, or completely stopping) the infiltration of cancer cells or tumor cells into surrounding organs; (5) inhibiting (i.e., reducing, slowing down, or completely stopping) metastasis; (6) enhancing anti-tumor immune responses, which may but need not result in tumor regression or rejection, or (7) alleviating to some extent one or more symptoms associated with cancer or tumors. A therapeutically effective amount may vary depending on factors such as the individual's disease state, age, sex, and weight, and the ability of one or more anticancer agents to elicit a desired response in the individual. A "therapeutically effective amount" is also an amount in which the therapeutically beneficial effects outweigh any toxic or deleterious effects.

[0027] The phrases "treating cancer" and "treatment of cancer" mean reducing, lowering, or inhibiting the replication of cancer cells; reducing, lowering, or inhibiting the spread of cancer (forming metastases); reducing the size of a tumor; reducing the number of tumors (i.e., reducing the tumor burden); reducing or lowering the number of cancer cells in the body; preventing the recurrence of cancer after surgical resection or other anti-cancer therapy; or ameliorating or alleviating the symptoms of a disease caused by cancer.

[0028] The term "expression vector" or "expression construct" refers to a vector suitable for transforming a host cell and containing a nucleic acid sequence that directs and / or controls (combines with a host cell) the expression of one or more heterologous coding regions operably linked thereto. An expression construct may include, but is not limited to, sequences that affect or control the transcription, translation, and, if introns are present, RNA splicing of a coding region operably linked thereto.

[0029] The term "expression cassette" refers to a nucleotide sequence comprising at least one coding sequence and sequence elements that direct transcription initiation and termination. An expression cassette may include, but is not limited to, additional sequences, including, but not limited to, promoters, enhancers, and sequences involved in post-transcriptional or post-translational processes.

[0030] When used in the claims and / or specification, the terms "inhibit," "reduce," or "prevent," or any variation of these terms, includes any measurable reduction or complete inhibition to achieve a desired result.

[0031] When used in conjunction with the term "comprising" in the claims and / or description, the term without a quantifier preceding it may mean "a", but it also complies with the meanings of "one or more", "at least one" and "one or more than one".

[0032] Throughout this application, the term "about" is used to indicate that a value includes the inherent variation for the device, the method for determining the value, or the variation that exists between study subjects.

[0033] The term "or" used in the claims is used to mean "and / or" unless explicitly stated to refer only to alternatives or the alternatives are mutually exclusive, although this disclosure supports a definition referring only to alternatives and "and / or." It is also contemplated that anything listed using the term "or" may also be explicitly excluded.

[0034] As used in this specification and claims, the words "comprise" (and any forms of including, such as "include" and "contain"), "have" (and any forms of having, such as "have" and "have"), "include" (and any forms of including, such as "includes" and "include"), or "includes" (and any forms of including, such as "includes" and "contain") are inclusive or open-ended, and do not exclude additional, unrecited elements or method steps.

[0035] In any embodiments discussed herein, the term "consisting of" or "consisting essentially of" may be substituted for the term "comprising."

[0036] It is contemplated that any embodiment discussed herein can be implemented with respect to any method or composition, and vice versa.In addition, compositions and kits can be used to implement methods.

[0037] Other embodiments are discussed throughout this application. Any embodiment discussed with respect to one aspect is also applicable to other aspects, and vice versa. The embodiments in the Examples section should be understood as embodiments applicable to all aspects. Other objects, features and advantages of the present invention will become apparent from the following detailed description. However, it should be understood that the detailed description and specific examples, although indicating preferred embodiments of the present invention, are given by way of illustration only, because various changes and modifications within the spirit and scope of the present invention will become apparent to those skilled in the art from the detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] The following drawings constitute part of this specification and are included to further illustrate certain aspects of the present invention. The present invention may be better understood by referring to one or more of these drawings in conjunction with the detailed description of the embodiments of the specification presented herein.

[0039] Figures 1A-1K.ELANE cleaves CD95 to selectively kill cancer cells. (A): Heat map summary of the effects of ELANE on survival, stress, and apoptosis pathways in cancer cells and healthy cells. For quantitative results, see Figure 2. (BC): Cancer cells were treated with ELANE (100nM) and CD95 cleavage was assessed by western blotting using anti-N-terminal (B) or anti-C-terminal (C) antibodies. *, lower molecular weight CD95 fragments. (D): Cancer cells or non-cancer cells were transduced to overexpress CD95 protein and the effect on ELANE-mediated apoptosis by ANXA5 was quantified at 30 minutes. n=2 / group. Transduction and CD95 overexpression see Fig. 1I . (E): ELANE cleavage of recombinant human CD95 N-terminal (aa 1-173) or C-terminal (aa212-335) proteins was assessed by SDS-PAGE and Coomassie blue staining. (F): Bands from (E) were digested with trypsin and analyzed by mass spectrometry to identify putative ELANE cleavage sites (i.e., peptides with non-trypsin ends). The major non-trypsin peptides were quantified by ion chromatograms. (G): Schematic representation of the ELANE cleavage sites in CD95. The heat map shows the overlap between the two CD95 cleavage sites and the ELANE sequence specificity (located at URL web.expasy.org). (H): ELANE cleavage of recombinant peptides corresponding to aa 214-231 and aa 317-335 in CD95 was monitored by mass spectrometry. (I): Cancer cells or non-cancer cells were treated with fluorescein-labeled ELANE for 10 minutes, and the uptake was visualized by immunofluorescence. (J): ELANE catalytic activity in cancer cell lysates after 30 min exposure to ELANE in the presence and absence of Dynasore (60 μM, an endocytosis inhibitor). Effect of Dynasore on the cancer cell killing ability of ELANE (measured by Calcein-AM). n=6 / group. (K): Cancer cells or non-cancer cells were transduced to overexpress various CD95 proteins, and cell viability in the absence of ELANE was determined by Calcein-AM. n=10 / group. *, p<0.05 Student's t-test.

[0040] Figures 2A-2DOverexpression of CD95 protein promotes ELANE killing of cancer cells. Polycistronic adenoviral vectors were prepared to express human and mouse CD95 sequences, followed by the encephalomyocarditis virus (EMCV) internal ribosome entry site and the dTomato sequence under the control of the cytomegalovirus (CMV) promoter. Human and murine cancer cells or non-cancer cells were transduced to overexpress full-length CD95, N-terminal CD95 (human: aa 1-209; mouse: aa 1-204), or C-terminal CD95 (human: aa 212-335; mouse: aa 204-327). (A): Transduction efficiency quantified by dTomato (left). CD95 levels in dTomato- and dTomato+ cells were quantified by geometric mean (MFI) (middle). ANXA5 levels in dTomato- and dTomato+ cells after 30 minutes of treatment with ELANE (40nM) (right). Representative data for A549 cells are shown. (BC): Quantification of transduction efficiency (B) and relative CD95 overexpression (C) in cancer cells and non-cancer cells. (D): Quantification of ANXA5 levels in mouse cancer cell lines (E0771, B16F10) after ELANE treatment (40 nM, 30 min). *, p<0.05 Student's t-test.

[0041] Figure 3 Efficacy of C1-2 peptide. Heat map of the effects of C1-2 expression on survival, stress, and apoptosis pathways in cancer and non-cancer cells.

[0042] Figure 4 Inducible expression system. Scheme for the expression of C (aa.157-335) or C1-2 (aa.221-331) using the doxycycline-inducible Tet-on system. C1-2 (fragment containing DD) after addition of doxycycline (in vitro and in vivo).

[0043] Figures 5A-5C Confirmation of C1-2 expression and selective killing of cancer cells. (A) MDA-MB-231 cells transduced with Tet-on C or C1-2 were treated with 2μg / mL doxycycline (2μg / mL) for 24 hours. Cell lysates were collected for Western blotting. Expression of C or C1-2 expression was confirmed. (B) MDA-MB-231 cells transduced with Tet-on C or C1-2 were treated with 0.2 or 2μg / mL doxycycline for 72 hours. Cell viability was measured by Calcein AM. Expression of C1-2 instead of C resulted in MDA-MB-231 cell death. (C) MCF10A cells transduced with Tet-on C1-2 were treated with 2μg / mL doxycycline. Cell viability was measured at different time points by Calcein AM. Expression of C1-2 in MCF10A cells did not result in cell death.

[0044] Figures 6A-6C MDA-MB-231 cell death was tested in vitro after C1-2 induction. (A) Various single colonies of MDA-MB-231 cells transduced with Tet-on C1-2 were treated with 2 μg / mL doxycycline (2 μg / mL) for 72 hours. Cell viability was measured by calcein AM. Different colonies had different susceptibility to death after C1-2 induction. (B) C1-2 expression in various single colonies of MDA-MB-231 cells transduced with Tet-on C1-2 after doxycycline treatment was measured by Western blotting (C), and levels at 24 hours correlated with percentage of death (normalized to full length). C1-2 expression is associated with MDA-MB-231 cell death. (C) Immunoblotting of C1-2 and full-length (FL) CD95 expression in various colonies.

[0045] Figures 7A-7C In vivo testing of MDA-MB-231 tumor regression after C1-2 induction. (A) Tumor weight. (B) Tumor cell counts (millions) (post-ficoll gradient). (C) Percentage of immune cells in tumors (mouse CD45+) measured by flow cytometry. DETAILED DESCRIPTION

[0046] ELANE cleaves CD95 to release proteolytic fragments that selectively kill a variety of cancer cells. These results, combined with previous work (Chen et al., Nature, 2010; Hadji et al., Cell Rep., 2014; Peter et al., Cell Death Differ., 2015), highlight the critical selective importance of CD95 for cancer cell viability. From a therapeutic perspective, delivery of CD95 fragments to tumors may overcome protective mechanisms and kill cancer cells through a genotype-independent mechanism with a broad therapeutic window. CD95 degradation (generation of CD95 fragments) has been identified as a mechanism of action for ELANE to kill cancer cells, and further suggests that a wide range of proteases can mimic the CD95 degradation and cancer cell killing properties of ELANE. Aspects of the present invention are based in part on the following observations. Treatment of ELANE or neutrophil conditioned medium with alpha-1-antitrypsin or PMSF (two irreversible, non-competitive ELANE inhibitors) protects cancer cells from apoptosis. ELANE degrades the C-terminal domain of purified CD95. Importantly, this cleavage pattern is distinct from that produced by MMP7, which was previously shown to cleave the extracellular N-terminal domain of CD95, thereby protecting cancer cells from FASL-mediated apoptosis (Strand et al., Oncogene, 2004).

[0047] Certain embodiments relate to therapeutic or anticancer compositions comprising various combinations of anticancer peptides or variants thereof, expression vectors or expression cassettes encoding them. In certain aspects, the peptide composition may include one or more than one peptide comprising, consisting essentially of, or consisting of: the amino acid sequence or Segment and / or and / or Certain embodiments relate to one or more than one peptide or variant thereof having an amino acid sequence that is more than 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80 94, 96, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, or 124 consecutive amino acids, including all values ​​and ranges therebetween, having 90, 92, 94, 96, 98, 99 to 100% identity.The functional segment of the anticancer peptide can be selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 1, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118 or 119 and ends at amino acid position 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123 or 124. In certain aspects, the anti-cancer peptides described herein can be modified by chemical modification of amino acid side chains (e.g., cross-linking, glycosylation, etc.) or by including a heterologous peptide sequence at the amino or carboxyl terminus of the peptide.

[0048] I. Polypeptide compositions and preparations

[0049] In certain embodiments, polypeptides and peptides include polypeptides having amino acid sequences SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 and / or SEQ ID NO:5 and functional segments thereof. "Polypeptide" refers to any peptide or protein comprising amino acids connected by peptide bonds or modified peptide bonds. "Polypeptides" may include short-chain polypeptides, including peptides, oligopeptides or oligomers, and long-chain polypeptides, including proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. "Polypeptides" include amino acid sequences modified by natural processes, such as post-translational processing, or by chemical modifications or other synthetic techniques well known in the art. Modifications may occur anywhere in a polypeptide, including the peptide backbone, amino acid side chains, and amino or carboxyl termini. It should be understood that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. In addition, a given polypeptide may contain multiple types of modifications. Modifications include terminal fusions (N- and / or C-terminus), acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer RNA-mediated addition of amino acids to protein, such as arginylation, and ubiquitination.

[0050] A variety of detectable labels can be attached to the polypeptides and variants thereof. For flow cytometric applications for extracellular and intracellular detection, commonly used fluorophores can be fluorescein isothiocyanate (FITC), allophycocyanin (APC), R-phycoerythrin (PE), apigenin chlorophyll protein (PerCP), Texas Red, Cy3, Cy5 fluorescence resonance energy tandem fluorophores such as PerCPCy5.5, PE-Cy5, PE-Cy5.5, PE-Cy7, PE-Texas Red and APC-Cy7. Other fluorophores include, among others, Alexa Fluor. 350. Alexa 488、Alexa 25 532. Alexa 546. Alexa 568. Alexa 594. Alexa 647 (monoclonal antibody labeling kit, purchased from Molecular Probes, Inc., Eugene, OR, USA), BODIPY dyes such as BODIPY 493 / 503, BODIPY FL, BODIPY R6G, BODIPY 530 / 550, BODIPY TMR, BODIPY 558 / 568, BODIPY 558 / 568, BODIPY 564 / 570, BODIPY 576 / 589, BODIPY 581 / 591, BODIPY TR, BODIPY 630 / 650, BODIPY 650 / 665, Cascade Blue, Cascade Yellow, Yellow), Dansyl chloride (Dansyl), Lissamine Rhodamine B, Ocean Blue, Oregon Green 488, Oregon Green 514, Pacific Blue, Rhodamine 6G, Rhodamine Green, Rhodamine Red, Tetramethylrhodamine, Texas Red (available from Molecular Probes, Inc., Eugene, OR, USA, and Cy2, Cy3, Cy3.5, Cy5, Cy5.5, Cy7. For secondary detection using labeled avidin, streptavidin, capped avidin, or neutravidin, it may be useful to label the polypeptide with biotin. The polypeptide may be labeled with a radioactive isotope, such as 33 P. 32 P. 35 S. 3 H and 125 I. As another example, when the polypeptide can be used for targeted radiation therapy, the label can be 3 H. 228 Th, 227 Ac, 225 Ac, 223 Ra, 213 Bi, 212 Pb, 212 Bi, 211 At 203 Pb, 194 Os, 188 Re, 186 Re, 153 Sm, 149 Tb, 131 I. 125 I. 111 In, 105 Rh, 99 mTc, 97 Such as 90 Y. 90 Sr. 88Y. 72 Se, 67 Cu or 47 Sc.

[0051] The term "isolated" may refer to a nucleic acid or polypeptide that is substantially free of the cellular material, bacterial material, viral material, or culture medium (when produced by recombinant DNA techniques), or chemical precursors or other chemicals (when chemically synthesized) from which it was originally derived. In addition, an isolated polypeptide refers to a polypeptide that can be administered to a subject as an isolated polypeptide; in other words, if the polypeptide is adhered to a chromatographic column or embedded in a gel, it cannot be simply considered "isolated". In addition, an "isolated nucleic acid fragment" or "isolated peptide" is a nucleic acid or protein fragment that does not exist naturally as a fragment and / or is not normally in a functional state.

[0052] The term "amino acid" or "residue" is understood to mean a compound containing an amino group (NH2), a carboxylic acid group (COOH) and any of a variety of side groups, which has the basic formula NH2CHRCOOH and is linked together by peptide bonds to form proteins. Amino acids can be, for example, acidic, basic, aromatic, polar or derivatized. Non-standard amino acids may be referred to as "non-canonical" amino acids. Amino acids naturally occur in α and L-forms, however, β and D-forms of amino acids can also be prepared.

[0053] A single-letter abbreviation system is commonly used to identify twenty "canonical" amino acid residues that are commonly incorporated into naturally occurring peptides and proteins, and these names are well known in the art. Such single-letter abbreviations are completely interchangeable in meaning with three-letter abbreviations or non-abbreviated amino acid names. Canonical amino acids and their three-letter and single-letter codes include alanine (Ala) A, glutamine (Gln) Q, leucine (Leu) L, serine (Ser) S, arginine (Arg) R, glutamic acid (Glu) E, lysine (Lys) K, threonine (Thr) T, asparagine (Asn) N, glycine (Gly) G, methionine (Met) M, tryptophan (Trp) W, aspartic acid (Asp) D, histidine (His) H, phenylalanine (Phe) F, tyrosine (Tyr) Y, cysteine ​​(Cys) C, isoleucine (Ile) I, proline (Pro) P, and valine (Val) V.

[0054] Some embodiments also include variants of polypeptides described herein. Variants of the disclosed polypeptides can be produced by adding or inserting amino acids, amino acid deletions, amino acid substitutions and / or chemical derivatization of amino acid residues in the polypeptide sequence. Those skilled in the art can determine the desired amino acid substitutions (whether conservative or non-conservative) according to the guidance provided herein for increasing stability, while maintaining or enhancing polypeptide effectiveness. In some embodiments, conservative amino acid substitutions can encompass non-naturally occurring amino acid residues, which are typically introduced by chemical peptide synthesis rather than by biological system synthesis.

[0055] Conservative modifications can produce peptides with similar functional, physical and chemical properties to the peptide to which such modifications were made. In contrast, substantial modification of the functional and / or chemical properties of a peptide can be achieved by selecting substitutions in the amino acid sequence that have a significantly different effect on maintaining (a) the structure of the molecular backbone in the region of the substitution, e.g., as an alpha-helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the size of the molecule. For example, a "conservative amino acid substitution" can involve replacing a natural amino acid residue with a non-natural residue, thereby having little effect on the polarity or charge of the amino acid residue at that position.

[0056] Recombinant DNA and / or RNA-mediated protein expression and protein engineering techniques or any other method for preparing peptides can be used to prepare the polypeptides disclosed herein or express the polypeptides disclosed herein in target cells or tissues. The term "recombinant" should be understood to mean that the material (e.g., nucleic acid or polypeptide) has been artificially or synthetically (i.e., non-naturally) changed by human intervention. The material can be changed in its natural environment or natural state or removed from its natural environment or natural state. For example, "recombinant nucleic acid" is made by recombining nucleic acids, such as in cloning, DNA shuffling or other well-known molecular biology processes. Examples of such molecular biological methods can be found in Maniatis et al., Molecular Cloning. A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1982. "Recombinant DNA molecules" are composed of DNA fragments connected together by such molecular biological techniques. As used herein, the term "recombinant protein" or "recombinant polypeptide" refers to a protein molecule expressed using a recombinant DNA molecule. "Recombinant host cell" is a cell containing and / or expressing a recombinant nucleic acid.

[0057] The polypeptide can be prepared in a transformed host cell according to methods known to those skilled in the art. In short, a recombinant DNA molecule or construct encoding the peptide is prepared. Methods for preparing such DNA molecules are well known in the art. For example, a suitable restriction endonuclease can be used to excise the sequence encoding the peptide from the DNA. Any of a large number of available and well-known host cells can be used in the practice of various embodiments. The selection of a specific host depends on many factors, including, for example, compatibility with the selected expression vector, toxicity of the polypeptide encoded by the DNA molecule, conversion rate, ease of polypeptide recovery, expression characteristics, biosafety and cost, etc. It is recognized that not all hosts may have an equivalent effect on the expression of a specific DNA sequence, and a balance should be struck between these factors. In these general guidelines, microbial host cells available in culture include bacteria (e.g., Escherichia coli), yeast (e.g., Saccharomyces cerevisiae) and other fungal cells, insect cells, plant cells, mammalian (including human) cells, such as CHO cells and HEK293 cells. Modifications can also be made at the DNA level. The DNA sequence encoding the peptide can be changed to codons that are more compatible with the selected host cell. For Escherichia coli, optimized codons are known in the art. Codons can be replaced to eliminate restriction sites or include silent restriction endonuclease sites, which can help process DNA in selected host cells. Next, cultivate and purify the transformed host. Host cells can be cultivated under conventional fermentation conditions to express required polypeptides. In addition, the DNA is optionally also 5' of the fusion protein to the coding region encoding a signal peptide sequence (for example, a secretion signal peptide) operably connected to the expressed polypeptide.

[0058] Polypeptides can also be prepared by synthetic methods. Solid phase synthesis can be used as a technique for preparing individual polypeptides because it is the most cost-effective method for preparing small peptides. For example, well-known solid phase synthesis techniques include the use of protecting groups, linkers, and solid supports, as well as specific protection and deprotection reaction conditions, linker cleavage conditions, the use of scavengers, and other aspects of solid phase peptide synthesis. Suitable techniques are well known in the art. See, for example, Merrifield, Chem. Polypeptides, Katsoyannis and Panayotis eds., pp. 335-361, 1973; Merrifield, J. Am. Chem. Soc. 85:2149, 1963; Davis et al., Biochem. Intl. 10:394-414, 1985; Stewart and Young, Solid Phase Peptide Synthesis, 1969; US Patent 3,941,763; Finn et al., The Proteins, 3rd ed., 2:105-253, 1976; and Erickson et al., The Proteins, 3rd ed., 2:257-527, 1976; "Protecting Groups in Organic Synthesis," 3rd ed., TWGreene andP.GMWuts,Eds.,John Wiley & Sons, Inc., 1999; Nova Biochem Catalog, 2000; "Synthetic Peptides, A User's Guide," GAGrant, Ed., WH Freeman & Company, New York, NY, 1992; "Advanced Chemtech Handbook of Combinatorial & Solid Phase Organic Chemistry," WD Bennet, JW Christensen, LK Hamaker, ML Peterson, MRRhodes, and H. H. Saneii, Eds., Advanced Chemtech, 1998; "Principles of Peptide Synthesis, 2nd.," M. Bodanszky, Ed., Springer-Verlag, 1993; "The Practice of Peptide Synthesis, 2nd ed.,"M. Bodanszky and A.Bodanszky,Eds.,Springer-Verlag,1994;"ProtectingGroups,"PJKocienski,Ed.,Georg Thieme Verlag,Stuttgart,Germany,1994;"FmocSolid Phase Peptide Synthesis,A Practical Approach,"WCChan and PDWhite,Eds.,Oxford Press,2000;GBFields et al.,Synthetic Peptides: A User's Guide, 77-183, 1990. .

[0059] Compositions comprising polypeptides, carriers (e.g., carriers) or half-life extension moieties that are covalently linked, attached or bound to another peptide directly or indirectly through a linker moiety are "conjugates" or "conjugated" molecules, whether conjugated by chemical methods (e.g., post-translation or post-synthesis) or by recombinant fusion. The conjugation of polypeptides can be carried out through the N-terminus and / or C-terminus of the polypeptide, or can be carried out in the middle of the primary amino acid sequence of the peptide. Due to the specificity of the polypeptide to cancer cells, the polypeptide can be coupled to other cytotoxic moieties to promote specific delivery to cancer cells and enhance the cytotoxicity of the polypeptides described herein. The linker can be used to produce a fusion protein that allows the introduction of additional moieties to enhance the killing or positioning of the polypeptide. The specific moieties of interest may include chemotherapeutic agents, pro-apoptotic factors, targeted therapeutic agents (e.g., kinase inhibitors, etc.) or other agents that promote killing.

[0060] In some embodiments, 1, 2, 3 or 4 polypeptides are coupled or encapsulated in the same or different delivery vehicles, such as carriers (e.g., particles) or liposomes. In some embodiments, the coupling of one or more polypeptides to a carrier includes one or more covalent and / or non-covalent interactions. In one embodiment, the carrier is a metal or polymer particle. In one embodiment, the carrier is a liposome. The size of the particle can be micrometer-scale or nanometer-scale. In some aspects, the diameter of the particle is at least, at most, or about 0.1 μm to at least, at most, or about 10 μm. On the other hand, the average diameter of the particle is at least, at most, or about 0.3 μm to at least, at most, or about 5 μm, 0.5 μm to at least, at most, or about 3 μm, or 0.2 μm to at least, at most, or about 2 μm. In some aspects, the particles may have an average diameter of at least, at most, or about 0.1 μm, or at least, at most, or about 0.2 μm, or at least, at most, or about 0.3 μm, or at least, at most, or about 0.4 μm, or at least, at most, or about 0.5 μm, or at least, at most, or about 1.0 μm, or at least, at most, or about 1.5 μm, or at least, at most, or about 2.0 μm, or at least, at most, or about 2.5 μm, or at least, at most, or about 3.0 μm, or at least, at most, or about 3.5 μm, or at least, at most, or about 4.0 μm, or at least up to and including about 4.5 μm, or at least, at most, or about 5.0 μm, including all values ​​and ranges therebetween.

[0061] In some embodiments, the charge of the carrier (e.g., positive, negative, neutral) is selected to confer application-specific benefits (e.g., physiological compatibility, beneficial surface-peptide interactions, etc.). In some embodiments, the carrier has a net neutral charge or a net negative charge (e.g., to reduce nonspecific binding to the cell surface that is usually net negatively charged). In some cases, the carrier is coupled to multiple polypeptides and can have 2, 3, 4, 5, 6, 7, 8, 9, 10...20...50...100 or more than 100 copies or combinations of polypeptides of certain polypeptides exposed to the surface. In some embodiments, the carrier displays a single type of polypeptide. In some embodiments, the carrier displays a variety of different polypeptides on the surface.

[0062] As used herein, the terms "packaging", "encapsulation" and "encapsulation" refer to the introduction of a polypeptide into or association with a liposome or similar carrier. The polypeptide may be associated with the lipid bilayer or present in the aqueous interior of the liposome, or both.

[0063] Liposomes can be formed by standard vesicle-forming lipids, which generally include neutral and negatively charged phospholipids and sterols, such as cholesterol. The selection of lipids is usually guided by considerations such as the size of the liposomes and the stability of the liposomes in the bloodstream. Various types of lipids are used to produce liposomes. For example, it is found that useful amphipathic lipids are zwitterions, acidic lipids or cationic lipids. Examples of zwitterionic amphipathic lipids are phosphatidylcholine, phosphatidylethanolamine, sphingomyelin, etc. Examples of acidic amphipathic lipids are phosphatidylglycerol, phosphatidylserine, phosphatidylinositol, phosphatidic acid, etc. Examples of cationic amphipathic lipids are diacyltrimethylammonium propane, diacyldimethylammonium propane, stearylamine, etc. Examples of neutral lipids include diglycerides, such as diolein, monoolein dipalmitolein and mixed caprylic acid-capric glycerides; triglycerides, such as triolein, monoolein tripalmitolein, trilinolein, tricaprylin and trilaurin; and combinations thereof. Additionally, in some embodiments, cholesterol or phytosterols are used, for example, in the preparation of multivesicular liposomes.

[0064] Liposomes can be prepared using a variety of methods, such as, for example, Szoka et al., Ann.Rev.Biophys.Bioeng.9:467 (1980), U.S. Patents 4235871, 4501728 and 4837028, the entire contents of which are incorporated herein by reference. One method produces multilamellar vesicles of non-uniform size. In this method, the lipids forming the vesicles are dissolved in a suitable organic solvent or solvent system and dried under vacuum or inert gas to form a thin lipid film. Alternatively, the lipids can be dissolved in a suitable solvent such as tert-butyl alcohol and then lyophilized to form a more homogeneous lipid mixture in a powdered form that is more easily hydrated. The film or powder is covered with a buffered aqueous solution and is usually hydrated within 15 to 60 minutes under stirring. By hydrating the lipids under more intense stirring conditions or by adding a solubilizing agent such as deoxycholate, the size distribution of the resulting multilamellar vesicles can be moved to a smaller size.

[0065] Multilamellar liposomes are formed, for example, by stirring the dispersion, preferably by using a thin film evaporator apparatus or by shaking or vortex mixing. Unilamellar vesicles are formed by applying shear forces to an aqueous dispersion of the lipid solid phase, for example by ultrasonic treatment or by applying shear forces using a microfluidization apparatus such as a homogenizer or a French press. Shear forces can also be applied by injection, freeze-thaw, dialyzing detergent solutions from lipids, or other known methods for preparing liposomes. The size of the liposomes can be controlled using a variety of known techniques, including controlling the duration of the shear forces.

[0066] "Uni-layer liposomes", also known as "uni-layer vesicles", are spherical vesicles comprising a lipid bilayer membrane that defines a single closed aqueous compartment. The bilayer membrane comprises two layers of lipids (or "lipid monolayers"), an inner layer and an outer layer. The hydrophilic heads of the outer layer of lipid molecules face the external aqueous environment, and the hydrophobic tails point inward toward the interior of the liposome. The inner layer of lipids is directly below the outer layer, with the heads of the lipids facing the aqueous interior of the liposome and the tails facing the tails of the outer layer of lipids.

[0067] "Multilamellar liposomes", also called "multilamellar vesicles" or "multilamellar vesicles", include more than one lipid bilayer membrane defining more than one enclosed aqueous compartment. The membranes are arranged concentrically so that different membranes are separated by aqueous compartments, like an onion.

[0068] II. Pharmaceutical Formulation and Administration

[0069] Embodiments relate to compositions comprising 1, 2, 3, 4 or more than 4 anticancer peptides or variants or functional segments thereof, and one or more of the following: a pharmaceutically acceptable diluent; a carrier; a solubilizer; an emulsifier; and / or a preservative. Such compositions may contain an effective amount of at least one anticancer agent or complex. Therefore, the use of one or more than one anticancer agent described herein in the preparation of a pharmaceutical composition is also included. Such compositions can be used to treat a variety of cancers.

[0070] Anticancer agents can be formulated into therapeutic compositions in various dosage forms, such as but not limited to liquid solutions or suspensions, tablets, pills, powders, suppositories, polymer microcapsules or microvesicles, liposomes, and injectable or infusible solutions. The preferred dosage form depends on the mode of administration and the specific disease targeted. The composition also preferably comprises a pharmaceutically acceptable carrier, vehicle, or adjuvant well known in the art.

[0071] Acceptable formulation components for use in pharmaceutical formulations are nontoxic to recipients at the dosages and concentrations employed. In addition to the provided anticancer agent, the composition may also contain components for modifying, maintaining or preserving, for example, pH, osmotic pressure, viscosity, clarity, color, isotonicity, odor, sterility, stability, dissolution or release rate, adsorption or penetration of the composition. Suitable substances for formulating pharmaceutical compositions include, but are not limited to, amino acids (e.g., glycine, glutamine, asparagine, arginine, or lysine); antimicrobial agents; antioxidants (e.g., ascorbic acid, sodium sulfite, or sodium bisulfite); buffers (e.g., acetate, borate, bicarbonate, Tris-HCl, citrate, phosphate, or other organic acids); bulking agents (e.g., mannitol or glycine); chelating agents (e.g., ethylenediaminetetraacetic acid (EDTA)); complexing agents (e.g., caffeine, polyvinylpyrrolidone, β-cyclodextrin, or hydroxypropyl-β-cyclodextrin); bulking agents; monosaccharides; disaccharides; and other sugars (e.g., glucose, mannose, or dextrin); proteins (e.g., serum albumin, gelatin, or immunoglobulins); colorants, flavorings, and diluents; emulsifiers; hydrophilic polymers (e.g., such as polyvinyl pyrrolidone); low molecular weight polypeptides; salt-forming counterions (such as sodium); preservatives (such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenylethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid or hydrogen peroxide); solvents (such as glycerol, propylene glycol or polyethylene glycol); sugar alcohols (such as mannitol or sorbitol); suspending agents; surfactants or wetting agents (such as pluronics, PEG, sorbitan esters, polysorbates such as polysorbate 20, polysorbate 80, triton, trimethylamine, lecithin, cholesterol, tyloxapol); stability enhancers (such as sucrose or sorbitol); tonicity enhancers (such as alkali metal halides, preferably sodium chloride or potassium chloride, mannitol, sorbitol); delivery vehicles; diluents; excipients and / or pharmaceutical adjuvants. (See Remington's Pharmaceutical Sciences, 18th ed., (AR Gennaro, ed.), 1990, Mack Publishing Company), which is incorporated herein by reference.

[0072] The formulation components are present in concentrations acceptable to the site of administration. Buffers are advantageously used to maintain the composition at physiological pH or slightly lower pH, typically maintained at a pH range of at least, at most, or about 4.0 to at least, at most, or about 8.5, or alternatively, maintained at a pH range of at least, at most, or about 5.0 to 8.0, including all values ​​and ranges therebetween. The pharmaceutical composition may include a TRIS buffer of at least, at most, or about pH 6.5 to 8.5 (including all values ​​and ranges therebetween), or an acetate buffer of at least, at most, or about pH 4.0 to 5.5 (including all values ​​and ranges therebetween), and may also include sorbitol or a suitable substitute thereof.

[0073] The pharmaceutical composition for in vivo administration is usually sterile. Sterilization can be achieved by filtration with a sterile filter membrane. If the composition is freeze-dried, sterilization can be performed before or after freeze-drying and reconstitution. The composition for parenteral administration can be stored in a lyophilized form or in a solution form. In some embodiments, the parenteral composition is placed in a container with a sterile access port, for example, an intravenous solution bag or a vial with a stopper that can be pierced by a hypodermic injection needle, or a sterile pre-filled syringe prepared for injection.

[0074] The above-mentioned compositions can be administered using conventional delivery methods, including but not limited to intravenous administration, intraperitoneal administration, oral administration, intralymphatic administration, subcutaneous administration, intraarterial administration, intramuscular administration, intrapleural administration, intrathecal administration, and perfusion by local catheter. Local administration (e.g., intratumoral administration) to the tumor in question is also contemplated. When the composition is administered by injection, it can be administered by continuous infusion or by single or multiple doses. For parenteral administration, the anti-metastatic agent can be administered in the form of a pyrogen-free parenteral acceptable aqueous solution, the aqueous solution comprising the desired anticancer agent in a pharmaceutically acceptable carrier. A particularly suitable carrier for parenteral injection is sterile distilled water, in which one or more than one anticancer agent is formulated as a sterile isotonic solution, appropriately preserved.

[0075] Once the pharmaceutical composition is formulated, it can be stored in a sterile vial in the form of a solution, suspension, gel, emulsion, solid or dehydrated or lyophilized powder. Such preparations can be stored in a ready-to-use form or in a reconstituted (e.g. lyophilized) form prior to administration.

[0076] If desired, stabilizers conventionally used in pharmaceutical compositions, such as sucrose, trehalose or glycine, may be used. Typically, such stabilizers will be added in minor amounts, such as at least, at most, or about 0.1 weight / volume % to at least, at most, or about 0.5 weight / volume %. Surfactant stabilizers, such as those conventionally used in pharmaceutical compositions, may also be added. -20 or -80 (ICI Americas, Inc., Bridgewater, NJ, USA).

[0077] The components used to formulate pharmaceutical compositions are preferably of high purity and substantially free of potentially harmful contaminants (e.g., at least National Food (NF) grade, usually at least analytical grade, more usually at least pharmaceutical grade). In addition, compositions intended for in vivo use are typically sterile. If a given compound must be synthesized prior to use, the resulting product is typically substantially free of any potentially toxic agents. Compositions for parenteral administration are also sterile, substantially isotonic, and prepared under GMP conditions.

[0078] For the compounds described herein (alone or as part of a pharmaceutical composition), such dosages are at least, up to, or about 0.001 mg / kg to 10 mg / kg body weight, preferably at least, up to, or about 1 to 5 mg / kg body weight, and most preferably 0.5 to 1 mg / kg body weight, including all values ​​and ranges therebetween.

[0079] The therapeutically effective dose can be readily determined by those skilled in the art and depends on the severity and course of the disease, the patient's health condition and response to treatment, the patient's age, weight, height, sex, previous medical history and the judgment of the attending physician.

[0080] In some methods, the cancer cells are tumor cells. The cancer cells may be in the patient's body. The patient may have a solid tumor. In this case, the embodiment may also include performing surgery on the patient, such as removing all or part of the tumor. The composition may be administered to the patient before, after, or simultaneously with the surgery. In other embodiments, the composition may also be administered to the patient directly, endoscopically, intratracheally, intratumorally, intravenously, intralesionally, intramuscularly, intraperitoneally, regionally, transdermally, topically, intraarterially, intravesically, or subcutaneously. The therapeutic composition may be administered 1 time, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, 11 times, 12 times, 13 times, 14 times, 15 times, 16 times, 17 times, 18 times, 19 times, 20 times, or more than 20 times; and the composition may be administered every 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, The invention relates to the invention to a pharmaceutical composition comprising the following: a) administering the pharmaceutical composition to a subject every 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, or every 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, or every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months.

[0081] The method may also include administering to the subject a second cancer therapy selected from chemotherapy, radiotherapy, immunotherapy, hormone therapy (or other targeted therapy) or gene therapy. The method may also include administering to the subject more than once 1, 2, 3, 4 or all 5 polypeptides or variants thereof. In certain aspects, the second cancer therapy may be administration of ELANE or a similar protease in combination with the anti-cancer peptides described herein.

[0082] The method for treating cancer can also include applying chemotherapy or radiotherapy to the patient, which can be applied more than once. Chemotherapy includes but is not limited to cisplatin (CDDP), carboplatin, procarbazine, nitrogen mustard, cyclophosphamide, camptothecin, ifosfamide, melphalan, chlorambucil, busulfan, nitrosourea, actinomycin D, daunorubicin, doxorubicin, bleomycin, plicamycin, mitomycin, etoposide (VP16), tamoxifen, taxotere, paclitaxel, transplatinum, 5-fluorouracil, methotrexate, gemcitabine, oxaliplatin, irinotecan, topotecan or any analog or derivative variant thereof. Radiotherapy includes but is not limited to X-ray irradiation, UV irradiation, gamma irradiation, electron beam irradiation or microwave. In addition, as part of the method, microtubule stabilizers can be applied to cells or patients, including but not limited to taxanes. It is particularly contemplated that any compound or derivative or analog can be used together with these combined therapies.

[0083] In some aspects, other therapeutic agents that can be used for cancer therapy in combination with the polypeptides described herein include anti-angiogenic agents. Many anti-angiogenic agents have been identified and are known in the art, including, for example, TNP-470, platelet factor 4, thrombospondin-1, tissue inhibitors of metalloproteinases (TIMP1 and TIMP2), prolactin (16-Kd fragment), angiostatin (38-Kd fragment of plasminogen), endostatin, bFGF soluble receptor, transforming growth factor β, interferon α, soluble KDR and FLT-1 receptor, placental proliferator-activated protein, and those listed by Carmeliet and Jain (2000). In one embodiment, the inhibitor can be used in combination with a VEGF antagonist or VEGF receptor antagonist, such as an anti-VEGF antibody, a VEGF variant, a soluble VEGF receptor fragment, an aptamer capable of blocking VEGF or VEGFR, a neutralizing anti-VEGFR antibody, a VEGFR tyrosine kinase inhibitor, and any combination thereof (e.g., the anti-hVEGF antibody A4.6.1, bevacizumab, or ranibizumab).

[0084] Immunotherapy or biological response modifier therapy can be used in combination with the therapies described herein. These therapies use the immune system to fight disease. Immunotherapy can help the immune system recognize cancer cells, or enhance the response to cancer cells. Immunotherapy includes active immunotherapy and passive immunotherapy. Active immunotherapy stimulates the body's own immune system, while passive immunotherapy generally uses immune system components produced outside the body.

[0085] Examples of active immunotherapy include, but are not limited to, vaccines, including cancer vaccines, tumor cell vaccines (autologous or allogeneic), viral vaccines, dendritic cell vaccines, antigen vaccines, anti-idiotypic vaccines, DNA vaccines, or tumor infiltrating lymphocyte (TIL) vaccines with interleukin 2 (IL-2), or lymphokine-activated killer (LAK) cell therapy.

[0086] Examples of passive immunotherapy include, but are not limited to, monoclonal antibodies and targeted therapies containing toxins. Monoclonal antibodies include naked antibodies and conjugated antibodies (also referred to as tag antibodies, labeled antibodies, or loaded antibodies). Naked monoclonal antibodies do not have a bound drug or radioactive material, while conjugated monoclonal antibodies are bound to, for example, chemotherapeutic drugs (chemical labels), radioactive particles (radiolabels), or toxins (immunotoxins).

[0087] In some embodiments, passive immunotherapy such as naked monoclonal antibody drugs can be used in combination with the polypeptide compositions described herein to treat cancer. Examples of these naked monoclonal antibody drugs include, but are not limited to, rituximab (Rittman), an antibody against CD20 antigen, which is used to treat, for example, B-cell non-Hodgkin's lymphoma; trastuzumab (Herceptin), an antibody against HER2 protein, which is used to treat, for example, advanced breast cancer; alemtuzumab (Campas), an antibody against CD52 antigen, which is used to treat, for example, B-cell chronic lymphocytic leukemia (B-CLL); cetuximab (Erbitux), an antibody against EGFR protein, which is used, for example, in combination with irinotecan to treat, for example, advanced colorectal cancer and head and neck cancer; bevacizumab (Avastin), an anti-angiogenic therapy, which can counteract VEGF protein and is used in combination with, for example, chemotherapy to treat, for example, metastatic colorectal cancer. Other examples of therapeutic antibodies that can be used include, but are not limited to: (trastuzumab) (Genentech, CA), which is a humanized anti-HER2 monoclonal antibody used to treat patients with metastatic breast cancer; (abciximab) (Centocor), which is an anti-glycoprotein IIb / IIIa receptor on platelets and is used to prevent blood clot formation; (daclizumab) (Roche Pharmaceuticals, Switzerland), an immunosuppressive humanized anti-CD25 monoclonal antibody used to prevent acute renal transplant rejection; PANOREX TM , which is a mouse anti-17-IA cell surface antigen IgG2a antibody (Glaxo Wellcome / Centocor); BEC2, which is a mouse anti-idiotypic (GD3 epitope) IgG antibody (ImClone system); IMC-C225, which is a chimeric anti-EGFR IgG antibody (ImClone system); VITAXINTM , which is a humanized anti-αVβ3 integrin antibody (Applied Molecular Evolution / MedImmune); Campath1H / LDP-03, which is a humanized anti-CD52 IgG1 antibody (Leukosite); SmartM195, which is a humanized anti-CD33 IgG antibody (Protein Design Laboratory / Kanebo); RITUXAN TM , which is a chimeric anti-CD20 IgG1 antibody (IDEC Pharm / Genentech, Roche / Zettyaku); LYMPHOCIDE TM , which is a humanized anti-CD22 IgG antibody (Immunomedics); LYMPHOCIDE TM Y-90 (Immunomedics); Lymphoscan (Tc-99m labeling; radiography; Immunomedics); Nuvion (directed against CD3; Protein Design Labs); CM3, a humanized anti-ICAM3 antibody (ICOS Pharm); IDEC-114, a primatized anti-CD80 antibody (IDEC Pharm / Mitsubishi); ZEVALIN TM, which is a radiolabeled mouse anti-CD20 antibody (IDEC / ScheringAG); IDEC-131, which is a humanized anti-CD40L antibody (IDEC / Eisai); IDEC-151, which is a primatized anti-CD4 antibody (IDEC); IDEC-152, which is a primatized anti-CD23 antibody (IDEC / Seikagaku); SMART anti-CD3, which is a humanized anti-CD3 IgG (Protein Design Lab); 5G1.1, which is a humanized anti-complement factor 5 (C5) antibody (MexionPharm); D2E7, which is a humanized anti-TNF-a antibody (CAT / BASF); CDP870, which is a humanized anti-TNF-α Fab fragment (Celltech); IDEC-151, which is a primatized anti-CD4 IgG1 antibody (IDEC Pharm / Smith Kline Beecham); MDX-CD4, which is a humanized anti-CD4 IgG antibody (Medarex / Eisai / Genmab); CD20-streptavidin (+biotin-yttrium 90; NeoRx); CDP571, which is a humanized anti-TNF-α IgG4 antibody (Celltech); LDP-02, which is a humanized anti-α4β7 antibody (LeukoSite / Genentech); Orthodone OKT4A, which is a humanized anti-CD4 IgG antibody (Ortho Biotech); ANTOVA TM , which is a humanized anti-CD40L IgG antibody (Biogen); ANTEGREN TM , which is a humanized anti-VLA-4 IgG antibody (Elan); and CAT-152, which is a human anti-TGF-β2 antibody (Cambridge Ab Tech).

[0088] In some embodiments, passive immunotherapy, such as conjugated monoclonal antibodies, can be used in combination with the polypeptide compositions described herein to treat cancer. Examples of these conjugated monoclonal antibodies include, but are not limited to, the radiolabeled antibody Ibritumomab Tiuxetan (Zevalin), which delivers radioactivity directly to cancerous B lymphocytes for the treatment of, for example, B cell non-Hodgkin's lymphoma; the radiolabeled antibody Tositumomab (Bexxar), which is used to treat, for example, some types of non-Hodgkin's lymphoma; and the immunotoxin Gemtuzumab Ozomicin (Mylotarg) containing calicheamicin, which is used to treat, for example, acute myeloid leukemia (AML). BL22 is a conjugated monoclonal antibody for the treatment of, for example, hairy cell leukemia, immunotoxins for the treatment of, for example, leukemia, lymphoma, and brain tumors, and radiolabeled antibodies such as OncoScint, for example, for colorectal cancer and ovarian cancer, and ProstaScint, for example, for prostate cancer.

[0089] In some embodiments, targeted therapies containing toxins can be used in combination with the polypeptide compositions described herein to treat cancer. Targeted therapies containing toxins are toxins linked to growth factors, or in certain embodiments to polypeptides described herein, and do not contain antibodies.

[0090] Some embodiments also include the use of adjuvant immunotherapy in combination with the polypeptide compositions described herein, such adjuvant immunotherapy includes but is not limited to cytokines, such as granulocyte-macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), macrophage inflammatory protein (MIP)-1-α, interleukins (including IL-1, IL-2, IL-4, IL-6, IL-7, IL-12, IL-15, IL-18, IL-21 and IL-27), tumor necrosis factor (including TNF-α) and interferons (including IFN-α, IFN-β and IFN-γ); aluminum hydroxide (alum); Bacille Calmette-Guérin (BCG); keyhole limpet hemocyanin (KLH); Freund's incomplete adjuvant (IFA); QS-21; DETOX; levamisole; dinitrophenyl phene (DNP) and combinations thereof, such as a combination of an interleukin (e.g., IL-2) with other cytokines such as IFN-α.

[0091] Some embodiments also include the use of hormone therapy (anti-hormones) in combination with the polypeptide compositions described herein. Anti-hormones include, but are not limited to, drugs that regulate or inhibit the effects of hormones on tumors, such as antiestrogens and selective estrogen receptor modulators (SERMs), including, for example, tamoxifen (including Tamoxifen), raloxifene, droloxifene, 4-hydroxytamoxifen, troloxifene, keoxifene, LY117018, onasperone and FARESTON toremifene; aromatase inhibitors that inhibit aromatase to regulate adrenal estrogen production, such as 4(5)-imidazole, aminoglutarimide, Pregnane acetate, Exemestane, formestane, fadrozole, Vorozole, Letrozole and anastrozole; and antiandrogens, such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; and troxacitabine (a 1,3-dioxolane nucleoside cytosine analog); antisense oligonucleotides, particularly those that inhibit the expression of genes in signaling pathways involved in cell proliferation, such as PKC-α, Ralf, and H-Ras; ribozymes, such as inhibitors of VEGF expression (e.g. ribozymes) and HER2 expression inhibitors; vaccines, such as gene therapy vaccines, such as vaccine, Vaccines and vaccine; Ril-2; Topoisomerase 1 inhibitors; rmRH; and any pharmaceutically acceptable salt, acid or derivative thereof.

[0092] In some embodiments, the cancer for which the compositions described herein are administered can be bladder cancer, blood cancer, bone cancer, bone marrow cancer, brain cancer, breast cancer, colorectal cancer, esophageal cancer, gastrointestinal cancer, head cancer, kidney cancer, liver cancer, lung cancer, nasopharyngeal cancer, neck cancer, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, stomach cancer, testicular cancer, tongue cancer, or uterine cell cancer.

[0093] III. Expression and Expression Vectors

[0094] Nucleic acids encoding any polypeptide described herein (e.g., anticancer peptides) can be inserted into or used with any suitable expression system. Recombinant expression can be accomplished using vectors such as plasmids, viruses, etc. The vector can include a promoter operably linked to a nucleic acid encoding one or more than one polypeptide. The vector can also include other elements required for transcription and translation. As used herein, a vector refers to any vector containing exogenous DNA. Therefore, a vector is a substance that transports exogenous nucleic acid into a cell without degradation, and contains a promoter that produces nucleic acid expression in the cell to which it is delivered. Vectors include, but are not limited to, plasmids, viral nucleic acids, viruses, phage nucleic acids, phages, cosmids, and artificial chromosomes. A variety of prokaryotic and eukaryotic expression vectors suitable for carrying, encoding, and / or expressing nucleic acids encoding proteases can be produced. Such expression vectors include, for example, pET, pET3d, pCR2.1, pBAD, pUC, and yeast vectors. The vector can be used, for example, in a variety of in vivo and in vitro situations. The vector can be a gene therapy vector, such as an adenoviral vector, a lentiviral vector, or a CRISP-R vector.

[0095] The expression cassette, expression vector, and the sequence in the expression cassette or expression vector can be heterologous. As used herein, when the term "heterologous" is used for an expression cassette, expression vector, regulatory sequence, promoter, or nucleic acid, it refers to an expression cassette, expression vector, regulatory sequence, or nucleic acid that has been manipulated in a certain way. For example, a heterologous promoter can be a promoter that is non-naturally connected to the nucleic acid to be expressed, or a promoter that has been introduced into a cell through a cell transformation procedure. Heterologous nucleic acids or promoters also include nucleic acids or promoters that are naturally present in an organism but have been changed in a certain way (e.g., placed in a different chromosomal position, mutated, added in multiple copies, connected to a non-natural promoter or enhancer sequence, etc.). Heterologous nucleic acids may include sequences including cDNA. For example, when a heterologous coding region is connected to a nucleotide sequence containing a regulatory element such as a promoter, wherein the promoter is not found to be naturally associated with the coding region, or when a heterologous coding region is associated with a chromosome portion not found in nature (e.g., a gene expressed in a locus, wherein the protein encoded by the coding region is not normally expressed), the heterologous coding region can be distinguished from the endogenous coding region. Similarly, a heterologous promoter can be a promoter linked to a coding region where the promoter is not naturally associated with the coding region.

[0096] The viral vectors that can be used include those related to slow virus, adenovirus, adeno-associated virus, herpes virus, vaccinia virus, polio virus, AIDS virus, neurotrophic virus, Sindbis and other viruses. Also useful are any virus families with these viral characteristics, which make them also suitable for use as vectors. Retroviral vectors that can be used include those described in Verma, IM, Retroviral vectors for gene transfer. In Microbiology-1985, American Society for Microbiology, pp. 229-232, Washington, (1985). For example, such retroviral vectors can include Maloney murine leukemia virus, MMLV and other retroviruses expressing the desired characteristics. Typically, viral vectors contain non-structural early genes, structural late genes, RNA polymerase III transcripts, reverse terminal repeats necessary for replication and encapsidation, and promoters that control viral genome transcription and replication. When the virus is engineered into a vector, one or more than one early gene is usually removed, and genes or gene / promoter boxes are inserted into the viral genome to replace the removed viral nucleic acid.

[0097] A variety of regulatory elements may be included in expression cassettes and / or expression vectors, including promoters, enhancers, translation initiation sequences, transcription termination sequences and other elements. A "promoter" is generally one or more DNA sequences that function when the transcription start site is in a relatively fixed position. For example, a promoter may be upstream of a nucleic acid segment encoding a protease. A "promoter" comprises core elements required for the basic interaction of RNA polymerase and transcription factors, and may comprise upstream elements and response elements. An "enhancer" generally refers to a DNA sequence that functions at an unfixed distance from the transcription start site, and an "enhancer" may be 5' or 3' of a transcription unit. In addition, an enhancer may be within an intron and within the coding sequence itself. They are generally 10 to 300 nucleotides in length and function in cis. The function of an enhancer is to enhance transcription of a nearby promoter. Like a promoter, an enhancer also generally comprises a response element that mediates transcriptional regulation. An enhancer generally determines the regulation of expression.

[0098] The expression vector used in the eukaryotic host cell (yeast, fungi, insects, plants, animals, humans or nucleated cells) may also contain sequences necessary for termination of transcription, which may affect the expression of the mRNA. These regions are transcribed as polyadenylation segments in the untranslated portion of the mRNA encoding the tissue factor protein. The 3' untranslated region also contains a transcription termination site. Preferably, the transcription unit also contains a polyadenylation region. An advantage of this region is that it increases the likelihood that the transcribed unit will be processed and transported like the mRNA. The identification and use of polyadenylation signals in expression constructs have been well established. Preferably, homologous polyadenylation signals are used in expression constructs.

[0099] The expression of one or more than one protease from expression cassette or expression vector can be controlled by any promoter that can be expressed in prokaryotic cells or eukaryotic cells. The example of operable prokaryotic promoter includes but is not limited to SP6, T7, T5, tac, bla, trp, gal, lac or maltose promoter. The example of operable eukaryotic promoter includes but is not limited to constitutive promoter, such as viral promoter, such as CMV, SV40 and RSV promoter, and adjustable promoter, such as inducible promoter or inhibitory promoter, such as tet promoter, hsp70 promoter and synthetic promoter regulated by CRE. The carrier for bacterial expression includes pGEX-5X-3, and the carrier for eukaryotic expression includes pCIneo-CMV.

[0100] The expression cassette or vector may comprise a nucleic acid sequence encoding a marker product. The marker product is used to determine whether the gene has been delivered to the cell and whether it is expressed after delivery. Preferred marker genes are the E. coli lacZ gene encoding beta-galactosidase and green fluorescent protein. In some embodiments, the marker may be a selective marker. When these selective markers are successfully transferred into the host cell, the transformed host cell can survive if placed under selection pressure. There are two widely used different categories of selection schemes. The first category is based on the use of cell metabolism and mutant cell lines, which lack the ability to grow independently of supplementary culture medium. The second category is dominant selection, which refers to the selection scheme used in any cell type and does not require the use of mutant cell lines. These schemes typically use drugs to prevent the growth of host cells. Those cells with new genes will express proteins that convey drug resistance and survive the selection. Examples of such dominant selection use the drugs neomycin (Southern P. and Berg, P., J. Molec. Appl. Genet. 1:327 (1982)), mycophenolic acid (Mulligan, RC and Berg, P. Science 209:1422 (1980)), or hygromycin (Sugden, B. et al., Mol. Cell. Biol. 5:410-413 (1985)).

[0101] Gene transfer can be obtained by direct transfer of genetic material in plasmids, viral vectors, viral nucleic acids, phage nucleic acids, phages, cosmids and artificial chromosomes, or by transferring genetic material in cells or vectors such as cationic liposomes or viruses. Such methods are well known in the art and are easily applicable to the methods described herein. Transfer vectors can be any nucleotide construct for delivering genes to cells (e.g., plasmids), or as part of a general strategy for delivering genes, such as as part of a recombinant retrovirus or adenovirus (Ram et al., Cancer Res. 53: 83-88, (1993)). Suitable means for transfection include viral vectors, chemical transfectants or physical and mechanical methods, such as electroporation and direct diffusion of DNA, such as Wolff et al., Science, 247, 1465-1468, (1990); and Wolff, Nature, 352, 815-818, (1991) described.

[0102] For example, nucleic acid molecules, expression cassettes encoding proteases, and / or vectors can be introduced into cells by any method, including but not limited to calcium-mediated transformation, electroporation, microinjection, lipofection, particle bombardment, etc. The cells can be expanded in culture and then administered to a subject, such as a mammal, such as a human. The amount or number of cells administered can vary, but about 10 cells can be used. 6 About 10 9 The amount of cells per cell. The cells are usually delivered in a physiological solution such as saline or buffered saline. The cells can also be delivered in a carrier such as liposomes, exosomes or microvesicles.

[0103] The protease can be produced by transgenic cells that produce exosomes or microvesicles containing the protease. Exosomes and microvesicles mediate the secretion of many of the proteins, lipids, mRNAs and microRNAs, interact with neighboring cells, and can transmit signals, proteins, lipids and nucleic acids between cells (see, e.g., Shen et al., J Biol Chem. 286 (16): 14383-14395 (2011); Hu et al., Frontiers in Genetics 3 (April 2012); Pegtel et al., Proc. Nat'l Acad Sci 107 (14): 6328-6333 (2010); WO / 2013 / 084000; each of which is incorporated herein by reference in its entirety).

[0104] Thus, transgenic cells having a heterologous expression cassette or expression vector expressing one or more than one protease can be administered to a subject, and the exosomes produced by the transgenic cells deliver the protease to the tumor and / or cancer cells of the subject.

[0105] According to the above content, the present disclosure relates to methods for producing vectors, particularly plasmids, cosmids, viruses and phages, which are routinely used in genetic engineering and gene therapy, and which vectors contain nucleic acid molecules encoding the polypeptide sequences of proteases defined herein. In some cases, the vector is an expression vector and / or a gene transfer or targeting vector. Expression vectors derived from viruses such as retroviruses, vaccinia viruses, adeno-associated viruses, herpes viruses or bovine papilloma viruses can be used to deliver the polynucleotides or vectors to a target cell population. Recombinant vectors can be constructed using methods well known to those skilled in the art. Alternatively, the nucleic acid molecules and vectors can be reconstructed into liposomes for delivery to target cells. The vectors containing nucleic acid molecules of the present disclosure can be transferred to host cells by well-known methods, which vary according to the type of cell host.

[0106] Another aspect of the present invention relates to a gene therapy vector comprising an anticancer peptide construct. Gene therapy vectors are known in the art and include, but are not limited to, lentiviral vectors, adenoviral vectors, adeno-associated viral vectors, plasmids, and the like. The construction of the gene therapy vector of the present invention can be performed by methods known in the art. In some aspects, the gene therapy vector can be about, up to, or at least 10, 100, 1000, 1×10 4 pcs, 1×10 5 pcs, 1×10 6 pcs, 1×10 7 pcs, 1×10 8 pcs, 1×10 9 pcs, 1×10 10 pcs, 1×10 11 pcs, 1×10 12 The amount of viral particles (VP) or colony forming units (CFU) is administered, including all values ​​and ranges therebetween.

[0107] As an example of a gene therapy vector, the expression cassette can be contained in a lentiviral vector. The therapeutic vector can be transduced into cells in vitro and the cells delivered to the patient. Similarly, the therapeutic vector of the present invention can be delivered directly to the patient.

[0108] IV. Examples

[0109] The following examples and drawings are included to illustrate preferred embodiments of the present invention. It will be appreciated by those skilled in the art that the techniques disclosed in the examples or drawings represent techniques that the inventors have found to work well in the practice of the present invention and therefore can be considered to constitute preferred modes for its practice. However, it will be appreciated by those skilled in the art based on this disclosure that many changes may be made to the disclosed specific embodiments and similar or similar results may still be obtained without departing from the spirit and scope of the present invention.

[0110] Example 1

[0111] Neutrophil elastase cleaves CD95 to broadly and safely kill cancer cells

[0112] A. Results

[0113] Human neutrophils release factors that selectively kill cancer cells. Human peripheral polymorphonuclear neutrophils (PMNs) have a short half-life in vivo (about 8 hours) and rapidly undergo apoptosis to release factors with effective antimicrobial properties outside the cell (Dancey et al., J Clin Invest., 1976; Nathan et al., Nat Rev Immunol., 2006). To determine whether apoptotic neutrophils also release factors that kill cancer cells, 35 different human / mouse cancer cells were treated with serum-free medium, which was conditioned by circulating purified PMNs (PMN medium) to apoptosis. PMN medium effectively killed all tested cancer cell lines within 24 hours. In sharp contrast, PMN medium did not kill any of the 6 human / mouse normal cells or non-cancer cells tested. Conditioned medium from omental neutrophils (ON) from healthy subjects also selectively kills cancer cells. However, mouse neutrophils from various sources and activation states lack this cancer cell killing ability.

[0114] The cancer cell killing ability of PMN culture medium was inhibited by culturing cancer cells in fetal bovine, mouse, or human serum. However, if serum was delivered 5 minutes after exposure to PMN culture medium under serum-free conditions, the serum was unable to rescue the cancer cells, suggesting that the serum contains inhibitors that directly antagonize one or more anticancer factors in PMN culture medium (see below). The dependence of PMN culture medium on serum-free conditions could explain why previous studies performed in the presence of serum have shown that human neutrophils require cell-cell contacts to kill cancer cells (Yan et al., Oncoimmunology, 2014).

[0115] To begin to understand the mechanism by which PMN culture kills cancer cells, representative studies focused on three cancer types with different mutation profiles: melanoma (MEL888, B16F10), lung cancer (A549, LLC1), and triple-negative breast cancer (MDA-MB-231, E0771). PMN culture was found to kill all of these cancer cells by inducing apoptosis.

[0116] Studies were performed to determine whether PMN culture could induce apoptosis in cancer cells in vivo. Mice were injected with various cancer cells in syngeneic models (E0771, LLC1, B16F10) and PDX models of triple-negative breast cancer (TNBC, 4195) to generate approximately 100 mm 3Tumors of different sizes. PMN medium was delivered intratumorally (IT) because serum antagonized the cancer killing ability of PMN medium in vitro. Tumors were injected with human serum albumin (HSA) or PMN medium once a day for 5 days, and apoptosis was examined by staining for TUNEL, cleaved PARP (cPARP), and cleaved CASP3 (cCASP3). In each model tested, PMN medium attenuated tumor growth and induced apoptosis in cancer cells. The effects in syngeneic models were not due to the injection of human proteins into immunocompetent mice, but because inactivation of bioactive factors in PMN medium prevented its antitumor effects. In contrast, medium from mouse bone marrow-derived neutrophils (BMDN) failed to attenuate tumorigenesis in vivo, consistent with their inability to kill cancer cells in vitro. Consistent with its lack of toxicity to normal cells or non-cancer cells in vitro, injection of PMN medium into the mammary fat pad of tumor-free C57BL / 6 mice (once a day for 5 days) did not induce apoptosis at the injection site, nor did it affect body weight, spleen weight, or liver function.

[0117] ELANE is the main anticancer protein released by human PMNs. The results of the study showed that PMNs release factors that selectively kill a variety of cancer cells in vitro and in vivo. In order to identify the responsible factors, a quantitative cancer cell killing assay was developed to track the bioactive factors, and boiling, dialysis, and microconcentrator (centricon) experiments were used to justify the search for proteins. Next, studies were conducted to purify the responsible proteins. PMN culture medium was clarified through a 0.22 μm filter and prepared for fractionation. Surprisingly, this step eliminated the cancer killing activity of PMN culture medium from 2 independent donors without reducing total protein levels, indicating selective consumption of bioactive proteins.

[0118] Shotgun proteomics analysis identified 890 proteins (≥2 peptides, FDR<1%) in PMN culture medium, of which only 2 were significantly reduced by filtration in both donors (G test, p<0.05, Bonferroni correction): elastase (ELANE) and eosinophil cationic protein (ECP). ELANE is a serine protease that has been previously shown to promote tumorigenesis (Houghton et al., Nat Med., 2010), while ECP is a pore-forming protein that is toxic to both cancer cells and healthy cells (Young et al., Nature, 1986).

[0119] Two approaches were used to determine whether ELANE and / or ECP were responsible for the selective cancer killing activity of PMN culture media. First, ELANE or ECP was immunodepleted from PMN culture media, and it was found that depletion of either protein attenuated the ability of PMN culture media to kill MDA-MB-231 cells. Second, cancer cells or normal cells or non-cancerous cells were treated with purified ELANE or ECP, and cell viability was monitored. ELANE killed MDA-MB-231 cells in a dose-dependent manner, and this effect was selective because it did not kill human monocyte-derived macrophages (HMDM). In contrast, ECP killed MDA-MB-231 cells only at doses that were also toxic to HMDM.

[0120] Next, MDA-MB-231 cells were treated with a concentration of ELANE (0.25 μg / mL) and ECP (0.05 μg / mL) in PMN culture medium. Although PMN culture medium levels of ECP were unable to kill these cells alone, they significantly enhanced the selective killing ability of ELANE, indicating a synergistic effect between the two proteins.

[0121] Since ELANE affects biological pathways through proteolysis (Pham, Nat Rev Immunol., 2006), it was hypothesized that its anticancer function may require catalytic activity and that ECP may enhance this activity to support synergistic killing. ELANE was treated with PMSF or alpha-1-antitrypsin (A1AT), inactivation was confirmed by chromogenic substrate activity assay, and it was found that catalytically inactive ELANE was no longer able to kill cancer cells. PMSF or A1AT treatment also abolished the ability of PMN culture to kill cancer cells in vitro and in vivo. These results suggest that ELANE is the main anticancer factor in PMN culture. In fact, the catalytic activity of ELANE in PMN culture from 9 healthy donors was closely correlated with its ability to kill MDA-MB-231 cells.

[0122] Understanding the anti-cancer function of human neutrophils through ELANE also helps explain why mouse neutrophils lack this ability. Although mouse ELANE kills cancer cells and mouse neutrophils contain catalytically active ELANE inside the cell and release ELANE during apoptosis, this released ELANE is catalytically inactive.

[0123] Studies were conducted to further determine whether ECP could enhance the catalytic activity of ELANE. ELANE was incubated with increasing concentrations of ECP and found to act as a type II allosteric activator of ELANE, in which ECP binds to ELANE with high affinity (K D =17 nM) binds to ELANE and catalyzes its conversion rate (k cat) increased by approximately 12-fold. Co-immunoprecipitation experiments confirmed that ECP binds to ELANE in human PMN culture medium. These results may explain why depleting ECP (which also depletes ELANE) from PMN culture medium attenuates its killing activity, even though ECP is not toxic to cancer cells at the doses present in PMN culture medium. In addition, since ECP has a high affinity for biological membranes (Young et al., Nature, 1986), these findings may help explain why filtration through a 0.22 μm filter selectively depletes ECP (and associated ELANE) from PMN culture medium. Looking ahead, ELANE is in the spotlight because it is both effective and safe in vitro, and the ability of ECP to enhance its catalytic activity can be mimicked by increasing the concentration of ELANE. In fact, higher doses of ELANE (3 μg / ml) effectively induced apoptosis in all cancer cell lines tested, but were not toxic to all normal cells or non-cancer cells tested.

[0124] ELANE selectively kills cancer cells by cleaving CD95. How does ELANE selectively kill cancer cells? Research has focused on the CD95 pathway because it is essential for the survival of a variety of cancer cells, but is largely dispensable for the survival of normal cells or non-cancerous cells (Chen et al., Nature, 2010), and the unique properties reflect the broad anti-cancer and low toxicity characteristics of ELANE. In addition, CD95 function can be regulated by proteolysis (Strand et al., Oncogene, 2004). Previous studies have shown that reducing CD95 in cancer cells using shRNA activates a powerful killing program characterized by inhibition of survival pathways and induction of DNA damage, mitochondrial ROS (MT ROS) and apoptotic effectors (Chen et al., Nature, 2010; Hadji, et al., Cell Rep, 2014). In contrast, this killing program was not induced in Cd95- / - normal cells or non-cancerous cells. It is therefore assumed that ELANE kills cancer cells through a mechanism involving CD95 cleavage. To begin to test this hypothesis, studies were performed to investigate whether ELANE could mimic the unique killing program caused by CD95 knockdown in cancer cells (Chen et al., Nature, 2010). ELANE treatment (i) inhibited at least one survival pathway (phosphorylation (p) of ERK, NFκB, or JNK), (ii) induced DNA damage (γH2AX), (iii) increased MT ROS, and (iv) activated pro-apoptotic pathways (cCASP3 and cPARP) in all 6 cancer cell lines tested (Figure 1a). Consistent with its lack of toxicity to normal or non-cancer cells, ELANE did not induce this program in all normal or non-cancer cells tested (Figure 1a).

[0125] Given that ELANE mimics the killing program observed in CD95 null cancer cells, it was determined whether ELANE could cleave CD95 in cancer cells and, if so, whether this resulted in a loss of CD95. Cancer cells were treated with ELANE and a lower molecular weight CD95 band was observed shortly before cell death (Figures 1b-1c). Although ELANE cleaved CD95 in all cancer cells tested, this cleavage did not result in a loss of full-length CD95, suggesting that CD95 cleavage by ELANE may kill cancer cells through a gain-of-function rather than a loss-of-function process. Consistent with this interpretation, overexpression of human CD95 (hCD95) or mouse CD95 (mCD95) in cancer cells did not prevent ELANE-mediated killing but rather accelerated killing (Figures 1d, 2).

[0126] To identify the ELANE cleavage site in hCD95, recombinant hCD95 protein corresponding to the N-terminal (aa.1-173 of SEQ ID NO: 1) or C-terminal (aa.212-335 of SEQ ID NO: 1) domain of hCD95 was incubated with ELANE. The results showed that ELANE preferentially cleaved the C-terminal domain (Figure 1e), and mass spectrometry analysis identified two major cleavage sites - site 1: V 220 and A 221 Between, site 2: I 321 and Q 332 1f). Both sites mapped well to the sequence specificity of ELANE, and studies using synthetic peptides confirmed these findings (Fig. 1g-1h).

[0127] Because CD95 is a plasma membrane protein and its C-terminal domain is intracellular, it is inferred that its anti-cancer function should require ELANE internalization. In fact, cancer cells rapidly internalized fluorescein-labeled ELANE, and internalized ELANE retained its catalytic activity (Figures 1i-1j). Treatment with the endocytosis inhibitor Dynasore attenuated ELANE uptake and protected cancer cells from apoptosis (Figure 1j). Dynasore also protected cancer cells from PMN medium-mediated killing. In addition, overexpression of the C-terminal domain of CD95 containing two cleavage sites (aa.212-335 of SEQ ID NO: 1) accelerated ELANE-mediated killing in human and mouse cancer cells, while overexpression of the N-terminal domain (aa 1-209 of SEQ ID NO: 1) had no effect (Figure 1d, Figure 2). These results indicate that the C-terminal CD95 proteolytic fragment released by ELANE cleavage may be sufficient to induce cancer cell apoptosis.

[0128] To further test this possibility, C-terminal hCD95 proteins cleaved by simulating ELANE at site 1 (aa.221-335 of SEQ ID NO: 1) and / or site 2 (aa.212-331 of SEQ ID NO: 1) were overexpressed, and it was found that expression of either of these proteins in the absence of ELANE induced cancer cell death (Figure 1k). In sharp contrast, overexpression of these same C-terminal hCD95 proteins in MCF10A cells or human omental adipose tissue fibroblasts from healthy subjects did not induce toxicity (Figure 1k). Therefore, although normal cells or non-cancer cells internalize ELANE, and the internalized ELANE is catalytically active, CD95 proteolytic fragments are not toxic to them (Figures 1a, 1d, 1i, 1k). These findings reinforce the specificity of this killing mechanism for cancer cells.

[0129] IT-delivered ELANE attenuates tumorigenesis. Having shown that ELANE selectively kills cancer cells in vitro, it was investigated whether IT-delivered ELANE could slow tumor progression in vivo. To establish therapeutic conditions, different doses of ELANE were injected into the E0771 TNBC model, and 12 μg / day was found to provide reproducible good therapeutic effects. It was demonstrated that inactivation of ELANE with PMSF abolished this therapeutic benefit, and PMSF-ELANE did not produce undesirable exacerbations. Finally, the results showed that injection of ELANE (12 μg / day) into the mammary fat pad of non-tumor-bearing C57BL6 mice did not produce significant side effects.

[0130] Next, the therapeutic potential of ELANE was explored in TNBC, lung cancer, and melanoma models. Athymic nude mice were injected with MDA-MB-231, A549, or MEL888 cells (xenograft models); SCID mice with M1 or 4195 tumors (TNBC PDX models); and C57BL / 6 mice with E0771, LLC1, or B16F10 cells (syngeneic models) to generate approximately 100 mm 3 At this time, PMSF-ELANE or ELANE (12 μg / day) was injected IT and the effect on tumor growth was monitored.

[0131] ELANE attenuated tumor growth in all models tested. Immunohistochemistry showed increased staining for TUNEL, cPARP, and cCASP3 in all ELANE-treated tumors, indicating that ELANE induces cancer cell apoptosis in vivo. In stark contrast, no evidence of apoptosis was found when ELANE was injected into tumor-free C57BL / 6 mice. These findings are consistent with in vitro mechanistic work, indicating that the anti-tumor effects of ELANE are both targeted and safe.

[0132] To explore whether cancer cells could acquire resistance to ELANE, a combination of in vitro and in vivo approaches was used. Repeated exposure of MDA-MB-231 cells to ELANE in vitro (7 exposures to produce approximately 90% mortality / exposure) did not confer resistance. Similarly, repeated treatment of E0771 or MEL888 tumors with ELANE in vivo (once a day for 7 days) did not attenuate the ability of ELANE to kill isolated cancer cells ex vivo. These findings suggest that it may be challenging to develop resistance to ELANE, similar to what has been previously reported in CD95 knockdown cancer cells (Murmann et al., Oncotarget, 2017).

[0133] IT-delivered ELANE induces CD8+ T cells to attack distant tumors. The dependence of ELANE's anticancer function on its catalytic activity and the abundance of serine protease inhibitors in the blood limit its therapeutic delivery to the IT route and serve as a barrier to access metastatic sites. This barrier could be overcome if the effects of ELANE on primary tumors could induce / activate immune cells to attack distant tumors, a property known as the abscopal effect (Ngwa et al., Rev Cancer, 2018).

[0134] To test this possibility, studies were performed to examine whether ELANE could increase tumor immune cells. In all three immune-competent models tested, ELANE increased dendritic cells (DCs), CD8 + T cells and CD8 + T effector cells (CD8 + T eff ). No increase in immune cells was observed if ELANE was injected into the mammary fat pad of tumor-free mice, nor was it observed if ELANE was injected into the contralateral site (i.e., opposite the tumor) of tumor-bearing mice, where it failed to attenuate tumorigenesis. Thus, ELANE increases innate and adaptive immune cells in tumors, an effect that is not due to an immune response to human ELANE.

[0135] Studies were conducted to determine whether treatment of primary tumors with ELANE generates an immune response to reduce tumorigenesis at distant sites. E0771 cells were injected into the left (1° tumors) and right (2° tumors) mammary fat pads to generate genetically identical tumors. Treatment of 1° tumors with ELANE (12 μg / day for 5 days) attenuated tumorigenesis at both sites, an effect that was specific because treatment of 1° E0071 tumors with ELANE did not affect tumorigenesis of 2° B16F10 tumors and was not due to ELANE overflow. To test this in another model, 1° B16F10 tumors were generated in the flank and B16F10 cells were injected into the tail vein to generate 2° lung metastases. Treatment of 1° tumors with ELANE (12 μg / day for 5 days) reduced the number of lung metastases. Importantly, depletion of CD8+ T cells attenuated the abscopal effects of ELANE in both models.

[0136] Notably, ELANE therapy produced "craters" in approximately 40% of tumors in all immunocompetent models tested. No pits were observed in tumor-free mice, nor were they observed in any immunocompromised cancer models, including CD8 - T cell-depleted C57BL / 6 mice. These data suggest that ELANE-mediated cancer cell killing and the subsequent adaptive immune response combine to form “pits” in tumors. However, the underlying mechanisms of pit formation and their importance for therapeutic efficacy require further investigation.

[0137] In vitro and in vivo expression of peptides. Figure 3 The effects of C1-2 expression on survival, stress, and apoptotic pathways in cancer (eg, MDA-MB-231, MEL888, and A549) and non-cancer cells (MCF10A and fibroblasts) are illustrated. Figure 4 The scheme of expressing C (aa.157-335) or C1-2 (aa.221-331) by the doxycycline-inducible Tet-on system. C1-2 (fragment containing DD) after addition of doxycycline (in vitro and in vivo). C1-2 expression can selectively kill cancer cells ( Figures 5A-5C In vitro testing confirmed that C1-2 induced cell death in MDA-MB-231 cells ( Figures 6A-6C In vivo testing demonstrated that C1-2 induced MDA-MB-231 tumor regression ( Figures 7A-7C ).

[0138] B. Methods

[0139] Regulation. Human studies were approved by the University of Chicago Institutional Review Board (IRB16-0321). Animal studies were approved by the University of Chicago Institutional Animal Care and Use Committee (ACUP72209, 72504). Cancer cell line and virus studies were approved by the Institutional Biosafety Committee (IBC1503).

[0140] Cell lines. Ovarian cancer cell lines—CAOV3, OVCAR3, OVCAR4, OVCAR5, A2780, A2780 / CP70, HeyA8, TykNu, SKOV3, ID8, and ID8p53- / - were kindly provided by Dr. Ernst Lengyel, University of Chicago. Breast cancer cell lines—MDA-MB-231, MDA-MB-231.BM1, MCF-7, M6C, E0771, and E0771.LMB were kindly provided by Dr. Marsha Rosner, University of Chicago. Colon cancer cell line RKO, glioblastoma cancer cell line T98G, osteosarcoma cell lines U-2OS and Saos-2, and hepatocellular carcinoma cell line HepG2 were kindly provided by Dr. Kay McLeod, University of Chicago. Lung cancer cell line NCI-H552 was kindly provided by Dr. Stephanie Huang, University of Chicago, and A549 and LLC1 cells were purchased from ATTC. Melanoma cell lines-B16F10, Mel888, Mel1106, and SK-MEL-28 cells were kindly provided by Dr. Thomas Gajewski, University of Chicago. Pancreatic cancer cell line PANC1 was kindly provided by Dr. Yamuna Krishnan, University of Chicago. Leukemia cell line K562 was kindly provided by Dr. Amittha Wickrema, University of Chicago. Cells were cultured in Dubecco's modified Eagles medium (DMEM; HyClone) containing 10% heat-inactivated FBS (Gemini Bio Products) and 1% penicillin / streptomycin (Gibco).

[0141] Prostate cancer cell lines - CWR22Rv1, LAPC4 and LNCaP were kindly provided by Dr. Donald Vander Griend, University of Chicago. Glioblastoma cell lines - SK-N-BE(2) and NBL-WN cells were kindly provided by Dr. Lucy Godley, University of Chicago. Cells were cultured in RPMI 1640 medium (Hyclone) containing 10% heat-inactivated FBS (Gemini Bio Products) and 1% penicillin / streptomycin (Gibco).

[0142] The mammary epithelial cell line MCF10A was kindly provided by Dr. Marsha Rosner of the University of Chicago. The cells were cultured in a medium containing 10% heat-inactivated FBS (Gemini Bio Products), 20 ng / mL EGF (Peprotech), 0.5 mg / ml hydrocortisone (Sigma), 100 ng / mL cholera toxin (Sigma), 10 μg / mL insulin (Sigma), and 1% penicillin / streptomycin (Gibco).

[0143] Primary human blood-derived cells. Human peripheral blood was donated from healthy volunteers with approval from the University of Chicago Institutional Review Board (IRB16-0321) and written consent. Blood was collected into EDTA-coated collection tubes (BD Vacutainer), and cells were separated with Ficoll Paque Plus (GE Healthcare) to obtain buffy coat (containing monocytes and lymphocytes) and bottom layer (containing neutrophils and erythrocytes). Human peripheral blood neutrophils (PMN)--PMNs were purified from the bottom layer by repeated RBC cutting as previously described (Kuhns et al., Curr Protoc Immunol., 2015). HMDM-monocytes were purified from buffy coat using CD14 microbeads (MiltenylBiotec) and differentiated into HMDM using human M-CSF (125ng / mL, R&D Systems) as previously described (Kratz et al., Cell Metab., 2014). Human lymphocytes - Human lymphocytes were isolated from buffy coats by collecting flow through from CD14 and CD16 microbeads (Miltenyi Biotec). The resulting cell population was compromised of approximately 90% T cells and approximately 10% B cells.

[0144] Primary human omental adipose-derived cells. Human omental adipose tissue was obtained from healthy volunteers with approval from the University of Chicago Institutional Review Board and written consent. Human omental neutrophils (ON) - Omental tissue was digested with collagenase type 1 (Worthington, 1 mg / mL) at 37°C with shaking at 130 rpm for 75 minutes to obtain stromal vascular cells (SVC). ON were isolated from SVC using CD16 microbeads (Miltenyi Biotec) according to the manufacturer's protocol. Human omental fibroblasts - Human primary fibroblasts were isolated from omental adipose tissue and cultured in DMEM (HyClone) containing 20% ​​heat-inactivated FBS (Gemini BioProducts) and 1% penicillin / streptomycin (Gibco) as previously described (Kenny atal., Int J Cancer, 2007).

[0145] Primary mouse cells. Unless otherwise specified, cells were isolated from 6-8 week old C57BL / 6 mice. Murine bone marrow derived macrophages (BMDM) - BMDM were differentiated from bone marrow stem cells using L cell conditioned medium as previously described (Kratz et al., Cell Metab., 2014). Mouse splenocytes - Mouse splenocytes were isolated as previously described (Reardon et al., Cell Rep, 2018). The resulting cells consisted of approximately 5% neutrophils, approximately 2% monocytes, approximately 38% T cells, and approximately 53% B cells. Mouse primary keratinocytes - Mouse primary keratinocytes were isolated and cultured in E low calcein medium containing 15% heat-inactivated FBS and 1% penicillin / streptomycin as previously described (Wu et al., Cell, 2008). Mouse bone marrow-derived neutrophils (BMDN) - BMDN were purified using Histopaque 1119 (Sigma) and Histopaque 10771 (Sigma) density gradient centrifugation as previously described (Swamydas et al., Curr Protoc Immunol., 2015). For PMA activation, BMDN were treated with PMA (100 nM, Abcam) for 15 min, washed and cultured to collect conditioned medium. Mouse thioglycolate-induced peritoneal neutrophils (PN) - PN were isolated from the peritoneal cavity 7 h after injection of 4% thioglycolate (3 mL / mouse, Sigma) as previously described (Swamydas et al., Curr Protoc Immunol., 2015). Mouse tumor-associated neutrophils (TAN) - E0771 cells were injected into the mammary fat pad of C57BL / 6 mice. When the tumor volume reached approximately 500 mm 3 Tumors were digested with collagenase type 4 (Worthington, 3 mg / mL) and hyaluronidase (Sigma, 1.5 mg / mL) at 37°C with shaking at 200 rpm for 45 minutes. TANs were purified using Ly6G microbeads (Miltenyi Biotec) according to the manufacturer's protocol. Murine lung neutrophils (LN) - Murine LNs were isolated from MMTV-PyMT mice aged 8-9 weeks (time point before metastatic dissemination). Lungs were digested with Liberase TL (Roche, 200 μg / mL) and DNase I (Sigma, 0.1 mg / mL) as previously described (Swamydas et al., Curr Protoc Immunol., 2015). Murine LNs were purified using Ly6G microbeads (Miltenyi Biotec) according to the manufacturer's protocol.

[0146] Neutrophil medium collection. Freshly isolated human or mouse neutrophils were plated in serum-free DMEM for 24 hours. Conditioned medium was collected, spun at 500 x g for 5 minutes, and medium protein levels were determined using the Bradford assay (Biorad).

[0147] PMN medium manipulation. For boiling, boil PMN medium at 95 °C for 5 min and then spin at 15,000 x g for 10 min to remove precipitated protein. For dialysis, place PMN medium into Slide-a-Lyzer TM cassette (3.5 kDa cutoff, ThermoFisher Scientific) and dialyzed against 2x4L PBS for 4 h at 4°C. For PMSF inactivation, PMN culture media were treated with PMSF (1 mM, Sigma) or A1AT (42 nM, Athens Research & Technology) and incubated at room temperature for up to 2 h. Residual PMSF was removed using a PD-10 desalting column (GE Healthcare Life). Inhibition of ELANE catalytic activity was confirmed using a chromogenic substrate activity assay (see below). For serum spiking experiments, human, mouse, or fetal bovine serum (1% or 10%) was added to PMN culture media before or after exposure to cancer cells. For immunodepletion studies, PMN culture media were treated with Pierce TM ELANE or ECP was immunoprecipitated using protein A / G magnetic beads (ThermoFisher Scientific) coupled to anti-ELANE (N2C3, GeneTx) or anti-ECP (MBS2535165, MyBioSource).

[0148] In vitro cell viability assays. Cancer cells or normal or non-cancer cells were plated in complete growth medium and grown to 80-90% confluence. Cells were washed with serum-free DMEM, treated with various therapeutic agents (e.g., PMN medium, ELANE, etc.) for 4-24 hours, and cell viability was assessed using several methods: Calcein-AM assay. 4-24 hours after treatment, cells were incubated with Calcein-AM (ThermoFisher Scientific, 4 ng / mL), washed with serum-free DMEM, and fluorescence was measured at 495 nm / 516 nm using a Synergy HT Multi-Mode Microplate Reader (Biotek). CASP3 activity assay - using Cell-associated CASP3 activity was measured 6 hours after treatment using the 3 / 7 assay system (Promega). Luminescence was measured using a Victor X3 luminometer (PerkinElmer). ANXA5 staining - 30 minutes to 6 hours after treatment, FITC Annexin V apoptosis detection kit (BD Pharmingen) was used according to the manufacturer's protocol. TM ) were used to stain the cells. TM II flow cytometer (BD Pharmingen TM )Analyze the samples.

[0149] Western blot analysis. Cells were cleaved with 1% SDS containing protease and phosphatase inhibitors (Sigma), and proteins were quantified using a BCA protein assay kit (Pierce). Proteins (10-20 μg) were separated on 10%, 12.5%, 15%, or 20% SDS-PAGE gels depending on the target protein, transferred to PVDF membranes (Millipore), blocked with 5% BSA (Sigma) in 0.1% TBS / Tween-20 for 2 h at room temperature, stained with primary and secondary antibodies, and visualized using an ECL detection kit (Biorad) and a LI-COR imager. Antibodies - Antibodies against pERK (4370), ERK (4695), pNFκB (3033), NFκB (8242), pJNK (4668), JNK (9252), CASP3 (9662), PARP (9542), H2AX (2595), TUBB (2125) were from Cell Signaling Technology. Antibodies against γH2AX (05-636-I, Millipore), ELANE (68672, Abcam), N-terminal CD95 (3070R, BioVision), and C-terminal CD95 (60196, Proteintech).

[0150] Mitochondrial ROS Measurement. Cells were treated with different doses of ELANE for 30 min, washed, labeled with CM-H2DCFDA dye (ThermoFisher Scientific, 10 μM) for 30 min at 37°C, and fluorescence was quantified by flow cytometry.

[0151] CD95 overexpression studies. Polycistronic adenoviral vectors were prepared to express human and mouse CD95 sequences followed by an encephalomyocarditis virus (EMCV) internal ribosome entry site and a dTomato sequence under the control of a cytomegalovirus (CMV) promoter (VectorBuilder). Human and murine cancer cells or normal or noncancerous cells were transduced to overexpress full-length CD95, N-terminal CD95 (human: aa 1-209; mouse: aa 1-204), C-terminal CD95 (human: aa 212-335; mouse: aa 204-327), or C-terminal CD95 that mimics ELANE cleavage at site 1 (human: aa 221-335), site 2 (human: aa 212-331), or both sites (aa 221-331). Cancer cells or normal cells or non-cancer cells were transduced with adenovirus at an MOI of 50-250 depending on the cell type, and the expression of dTomato and CD95 (human: 558814; mouse, mouse: 565130, BD Biosciences) was confirmed by flow cytometry. A vector encoding GFP (Vector Builders) was used as a control.

[0152] ELANE activity assay. The catalytic activity was measured using the chromogenic substrate N-methoxysuccinyl-Ala-Ala-Pro-Val p-nitroanilide (Sigma, 100 μg / mL) according to the manufacturer's protocol. The absorbance was measured at 405 nm using an accuSkan GO UV / Vis microplate spectrophotometer (ThermoFisher Scientific). For inactivation, ELANE was incubated with PMSF (1 mM, Sigma) or A1AT (42 nM, Athens Research & Technology) for 2 h. Residual PMSF was eliminated using a PD-10 desalting column (GE Healthcare Life). To monitor the effect of ECP on ELANE activity, ELANE (10 nM) was incubated with different doses of ECP (0-180 nM) at various substrate concentrations (0-1.7 mM).

[0153] Recombinant mouse ELANE activation. Recombinant mouse ELANE (50 μg / mL) was activated with CTSC (50 μg / mL) according to the manufacturer's protocol (R&D Systems).

[0154] Shotgun proteomic analysis. PMN culture medium from 2 independent donors was passed through a 0.22 μm filter (MilliporeSigma). Pre- and post-filtered culture medium (50 μg) was digested with trypsin.

[0155] Identification of the ELANE cleavage site in CD95 by mass spectrometry. Recombinant human C-terminal CD95 (aa212-335, MyBioSource, 10 μg) or recombinant N-terminal CD95 (aa 1-173, ThermoFisher Scientific, 10 μg) was digested with human ELANE (0.1 μg) at 37°C for 2 hours and the reaction was terminated with SDS-PAGE loading buffer. The proteins were run on a 20% SDS-PAGE gel, stained with Coomassie blue (ThermoFisher Scientific), and the bands were excised for mass spectrometry analysis. Proteins were extracted from the excised bands.

[0156] Recombinant peptides were analyzed by mass spectrometry. Recombinant peptides (10 μM) corresponding to aa214-(TLNPETVAINLSDVDLSK)-231 (SEQ ID NO: 6) or 317-(DITSDSENSNFRNEIQSLV)-335 (SEQ ID NO: 7) of human CD95 (ThermoFisher Scientific) were incubated with ELANE (0.1-0.2 μM) at 37° C. for 15-30 minutes. The reaction was terminated with 0.1% formic acid.

[0157] Tumor inoculation and treatment. MDA-MB-231 cells (2x10 6 ), A549 cells with Matrix type 3 (2x10 6 ) or MEL888 cells (2x10 6 ) were injected into athymic nude mice (Charles River); M1 or 4195 cells (50,000) were injected into NOD.SCID mice (JAX); E0771 cells (0.5×10 6 ), LLC1 cells (0.5x10 6 ) or B16F10 cells (1x10 6 ) were injected into C57BL / 6 mice (JAX). For TNBC models (MDA-MB-231, E0771, M1, 4195), cells were injected into the 4th mammary fat pad on the right flank. For all other models (A549, LLC1, MEL888, B16F10), cells were injected into the flank. Once tumors reached approximately 100 mm 3 ELANE or PMSF-ELANE (11.6 μg / 100 μL), or neutrophil medium or HSA (50 μg / 100 μL) were delivered intrathecally (IT) once daily for 5 days. Tumor volume was assessed with calipers when tumor volume in control mice reached >1000 mm 3 The experiment was terminated when .

[0158] Tumor immunohistochemistry. Tumors were fixed in 4% paraformaldehyde in PBS for 24 h, embedded in paraffin blocks, and sectioned (5 μm). Slides were stained with cCASP3 (9661) and cPARP (9625) antibodies from Cell Signaling Technology. Signals were visualized using the VECTASTAIN ABC kit (Vector Laboratories) or fluorescently labeled secondary antibodies (melanoma models). For TUNEL analysis, DeadEnd TM Colorimetric or fluorescent TUNEL system (Promega) was used for staining. Cell nuclei were labeled with hematoxylin or Hoechst 33342 (ThermoFisher Scientific). Images were acquired using a Nikon Eclipse Ti2 microscope and analyzed using NIS-Elements software.

[0159] Tumor immune cell analysis. Tumors were digested with collagenase type 4 (Worthington, 3 mg / mL) and hyaluronidase (Sigma, 1.5 mg / mL) at 37°C with shaking at 200 rpm for 45 minutes (E0771) or 30 minutes (LLC1 and B16F10). Cells were labeled with various antibodies and analyzed by flow cytometry. Data were quantified by FlowJo v.10.4.1. Antibodies included: CD45 (47-0451), CD11b (25-0112), MHCII (11-5321), CD4 (17-0041), CD8 (12-0081), CD44 (25-0441) from ThermoFisher Scientific, CD3 (560527), CD62L (561917) from BD Biosciences, and Ly6G (127614) from BioLegend.

[0160] For the E0771 model, 0.5x10 6 0.4x10 cells were injected into the 4th mammary fat pad on the right flank (1° tumor) of C57BL / 6 mice. 6 10 cells were injected into the 4th mammary fat pad of the left flank (2° tumor) of C57BL / 6 mice. Once the 1° tumor reached approximately 100 mm 3 ELANE or PMSF-ELANE (11.6 μg / 100 μL) was injected IT into 1° tumors once a day for 5 days, and the 1° and 2° tumor volumes were measured by caliper. For the B16F10 model, 0.5x10 6cells were injected into the flank (1° tumor). 7 days later, 0.2x10 6 Once 1° tumors reach approximately 100 mm 3 ELANE or PMSF-ELANE (11.6 μg / 100 μL) was injected IT into 1° tumors once daily for 5 days, and 1° tumor volumes were measured by caliper. Lungs were excised 10 days after the last ELANE treatment, and 2° lung metastases were counted. For CD8 + T cell depletion was performed by intravenous (IV) injection of anti-mouse CD8α (clone 2.43, Bio X Cell) or rat IgG2b (isotype control, Bio X Cell) (200 μg / injection) 3 days before the first ELANE treatment and weekly after the last ELANE treatment. + T cell depletion was confirmed by flow cytometry.

[0161] For "overflow control", 0.5x10 6 E0771 cells were injected into the 4th mammary fat pad of the left flank (2° tumor). ELANE or PMSF-ELANE (11.6 μg / 100 μL) was injected into the tumor-free 4th mammary fat pad of the right flank once a day for 5 consecutive days, and the 2° tumor volume was measured with a caliper.

[0162] For the "specificity control", 0.5x10 6 E0771 cells were injected into the fourth mammary fat pad on the right flank (1° tumor), and 7 days later, 1x10 6 B16F10 cells were injected into the flank (2° tumor). Once the 1° tumor reached approximately 100 mm 3 , ELANE or PMSF-ELANE (11.6 μg / 100 μL) was injected into 1° tumors once daily for 5 days, and the 1° and 2° tumor volumes were measured by caliper.

[0163] Evaluation of potential side effects. ELANE or PMSF-ELANE (11.6 μg / 100 μL) was injected into the 4th mammary fat pad of the right flank of tumor-free C57BL / 6 mice once a day for 5 days. One day after the last injection, the mice were studied for potential side effects. Body weight and spleen weight were measured. Apoptosis at the injection site was studied by isolating, fixing and staining mammary adipose tissue for TUNEL, cCASP3 and cPARP using the same methods as above for the tumors. The mammary adipose tissue immune cell population at the injection site was determined by flow cytometry using the same methods as above for the tumors. Liver function was assessed by measuring plasma ALT activity using an alanine aminotransferase colorimetric activity assay kit (Cayman Chemical).

[0164] In vivo testing. Two million Tet-on C1-2 transduced MDA-MB-231 cells were injected into the mammary glands of nude mice. Once the tumor reached approximately 80 to 100 mm 3 Mice were treated with either a doxycycline diet or intraperitoneal injection of doxycycline (50 mg / ml) every 5 days to induce the Tet-on system. Tumor growth was monitored. Tumors were isolated and digested on day 21 after doxycycline treatment, tumor weights were measured, tumor cell numbers were counted, and CD45+ cells were measured by flow cytometry.

[0165] Statistics. Statistical significance was determined by Student’s two-tailed unpaired t-test, except for proteomics studies. Linear regression, Michaelis-Menten, and hyperbolic curve fitting were performed using Prism v.7 software.

Claims

1. Use of a therapeutic composition in the preparation of a pharmaceutical composition for treating cancer, wherein an effective amount of the therapeutic composition is administered to a subject suffering from cancer, the therapeutic composition comprising an expression vector or expression cassette encoding one or more than one peptide of SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO:

5.

2. The use according to claim 1, wherein the amino acid sequence of the peptide is SEQ ID NO:

3.

3. The use according to claim 1, wherein the amino acid sequence of the peptide is SEQ ID NO:

4.

4. The use according to claim 1, wherein the amino acid sequence of the peptide is SEQ ID NO:

5.

5. The use according to claim 1, wherein the therapeutic composition is administered by injection.

6. The use according to claim 1, wherein the therapeutic composition is administered intratumorally.

7. The use according to claim 1, wherein the cancer is bladder cancer, blood cancer, bone cancer, bone marrow cancer, brain / nervous system cancer, breast cancer, colorectal cancer, esophageal cancer, gastrointestinal cancer, head cancer, kidney cancer, liver cancer, lung cancer, nasopharyngeal cancer, neck cancer, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, stomach cancer, testicular cancer, tongue cancer, or uterine cancer.

8. The use according to claim 1, wherein the expression vector is a viral vector.

9. The use according to claim 8, wherein the viral vector is a retrovirus, adenovirus, adeno-associated virus, herpes virus or vaccinia virus.

10. The use according to claim 9, wherein the retrovirus comprises a lentiviral vector.

11. The use according to claim 1, wherein a second anti-cancer therapy is administered.

12. The use according to claim 11, wherein the second anti-cancer therapy is chemotherapy, radiotherapy, immunotherapy or anti-hormonal therapy.

13. The use according to claim 11, wherein the second anticancer therapy is ELANE protease.

14. A method of inducing apoptosis in cancer cells, comprising contacting the cancer cells with an effective amount of an expression vector or expression cassette encoding one or more than one peptide of SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 5, wherein the method is an in vitro method.

15. The method of claim 14, wherein the cancer cell is in a bladder tumor, a blood tumor, a bone tumor, a myeloma, a brain / nervous system tumor, a breast tumor, a colorectal tumor, an esophageal tumor, a gastrointestinal tumor, a head tumor, a kidney tumor, a liver tumor, a lung tumor, a nasopharyngeal tumor, a neck tumor, an ovarian tumor, a pancreatic tumor, a prostate tumor, a skin tumor, a stomach tumor, a testicular tumor, a tongue tumor, or a uterine tumor.

16. The method of claim 15, wherein the expression vector is a viral vector.

17. The method of claim 16, wherein the viral vector is a retrovirus, an adenovirus, an adeno-associated virus, a herpes virus or a vaccinia virus.

18. The method of claim 17, wherein the retrovirus comprises a lentiviral vector.

19. A gene therapy vector composition comprising an anti-cancer peptide construct, comprising an expression vector or expression cassette encoding one or more than one peptide component of SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO:

5.

20. The composition according to claim 19, wherein the amino acid sequence of the peptide is SEQ ID NO:

3.

21. The composition of claim 19, wherein the amino acid sequence of the peptide is SEQ ID NO:

4.

22. The composition of claim 19, wherein the amino acid sequence of the peptide is SEQ ID NO:

5.

23. The composition of claim 19, wherein the expression vector is a viral vector.

24. The composition of claim 23, wherein the viral vector is a retrovirus, an adenovirus, an adeno-associated virus, a herpes virus or a vaccinia virus.

25. The composition of claim 24, wherein the retrovirus comprises a lentiviral vector.